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ABSTRACT 
Diabetes Mellitus is a metabolic disease characterized by the loss of beta cells from the islets, 
thereby disrupting islet composition and architecture which are important components that 
influence islet function. The experimental technique of pancreatic duct ligation (PDL), which 
is thought to induce the regeneration of beta cells within the adult pancreas, was investigated 
as a novel treatment strategy for diabetes. This study aimed at investigating the possibility that 
the PDL model may have the capacity to restore normal islet composition and architecture in 
diabetic animals, which could make it an effective approach to reverse diabetes. Male Wistar 
rats (n=55) were divided into three study groups: the normal control (NC) group, the diabetic 
control (DC) group consisting of five subgroups (day 0, 3, 5, 10 and 30) and the experimental 
(EX) group consisting of four subgroups (day 3, 5, 10 and 30). The experimental group was 
exposed to PDL. All pancreata were divided into a P1 portion (proximal to the point of 
ligature) and P2 portion (distal to the point of ligature) for histological assessment. Animals’ 
non-fasting blood glucose levels (BGLs) and body weights were monitored. The general 
morphology of the tissue was studied, while an immunohistochemical (IHC) study was 
performed to determine insulin, pancreatic polypeptide, glucagon and somatostatin protein 
expression in the P1 and P2 portions of the pancreas. From the IHC slides hormone fractions, 
staining intensity and distribution were determined as indication of islet composition and 
architecture. Despite apparent morphological recovery in the islet 30 days post-PDL, islet 
composition and architecture remained disrupted. Compared to diabetic animals, the proximal 
portion of the pancreas in experimental animals had a decreased beta cell fraction and 
increased delta cell fraction thirty days following PDL. These observed changes in islet 
composition in the part of the pancreas proximal to the ligature are novel findings. There was 
no change in the diabetic islet composition in the portion of the pancreas distal to the ligature 
thirty days following PDL. Furthermore, pancreatic duct ligation did not restore body weight 
or normoglycemia. We conclude that STZ disrupts islet composition and architecture and this 
could not be restored using PDL; we therefore suggest that a comparative study using a Type 
2 diabetic model, where there is limited damage to pre-existing beta cells, may yield different 
results.  
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OPSOMMING 
Diabetes Mellitus is ŉ metaboliese siekte wat deur die verlies van beta selle uit die eilande 
van Langerhans gekarakteriseer word. Hierdie verlies van beta selle ontwrig eiland 
komposisie en argitektuur, twee belangrike komponente van eiland funksie. Die 
eksperimentele tegnieke van pankreatiese buisafbinding (in Engels PDL), wat moontlik beta 
sel regenerasie in die volwasse pankreas kan induseer, is ondersoek as behandelings-strategie 
vir diabetes. Hierdie studie het ten doel gehad om die moontlikheid te ondersoek dat die PDL 
model die kapasiteit het om normale eiland komposisie en argitektuur te herstel in diabetiese 
diere, wat dit ŉ effektiewe benadering vir die omkeer van diabetes kan maak. Manlike Wistar 
rotte (n=55) was in 3 studie groepe verdeel: die normale kontrole (NC) groep, die diabetiese 
kontrole (DC) groep wat uit vyf subgroepe bestaan (dag 0, 3, 5, 10 en 30) en die 
eksperimentele (EX) groep wat uit vier subgroepe bestaan (dag 3, 5, 10 en 30). Die 
eksperimentele groep is aan PDL blootgestel. Alle pankreata is verdeel in ŉ P1 porsie 
(proksimaal tot die afbinding) en ŉ P2 porsie (distaal tot die afbinding) vir histologiese 
assessering. Die diere se nie-vastende bloed glukose vlakke en liggaamsgewig is gemonitor. 
Die algemene morfologie van die pankreas weefsel is bestudeer, terwyl ’n 
immunohistochemiese (IHC) studie gedoen is om insulien, pankreatiese polipeptied, glukagon 
en somatostatien proteïen uitdrukking in die P1 en P2 porsies van die pankreas te bepaal. 
Vanaf die IHC snitte is hormoon fraksie, kleur intensiteit en verspreiding bepaal as 
aanduidings van eiland komposisie en argitektuur. Ten spyte van ooglopende morfologiese 
herstel in die eilande op dag 30 na PDL, het eiland komposisie en argitektuur versteur gebly. 
In vergelyking met die diabetiese diere, het die proksimale deel van die pankreas van 
eksperimentele diere verlaagde beta sel fraksie en verhoogde delta sel fraksie getoon dertig 
dae na PDL. Die waarneming van veranderde komposisie in die deel van die pankreas 
proksimaal tot die afbinding is nuut. Daar was geen verandering in diabetiese eiland 
komposisie in die deel van die pankreas distaal tot die afbinding dertig dae na PDL nie. 
Verder het PDL nie liggaamsgewig of bloedsuiker genormaliseer nie. Ons gevolgtrekking is 
dat STZ eiland komposisie en argitektuur ontwrig en dat dit nie met PDL herstel kon word 
nie; daarom stel ons ŉ vergelykende studie in ŉ tipe 2 diabetes model voor, waar die skade 
aan reeds bestaande beta selle beperk is, wat ander resultate mag lewer. 
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1. INTRODUCTION 
The islets of Langerhans are clusters of endocrine cells dispersed within the exocrine tissue of 
the pancreas. These clusters are composed of four cell types: beta cells, alpha cells, delta cells 
and PP cells. Islets are important micro-organs that primarily function to maintain blood 
glucose homeostasis through the actions of insulin (secreted by beta cells) and glucagon 
(secreted by alpha cells). The cellular composition and architecture of the islets are important 
components that influence their function. 
A disruption in islet composition may result in metabolic disorders, like Diabetes Mellitus 
(DM), a disease in which beta cells are lost from the islets. This is accompanied by 
insufficient insulin production, consequently leading to chronically elevated blood glucose 
levels. Additionally, loss of insulin within the islet micro-environment allows increased 
glucagon production from the alpha cell type, which further contributes to hyperglycaemia.  
Restoring normal islet composition may be an effective approach to reverse diabetes. The 
pancreatic duct ligation (PDL) model is said to induce the formation of new beta cells in non-
diabetic animals. This same observation has been made in a diabetic animal model; however, 
the effects of PDL on islet composition (including non-beta cells) have not been established. 
Since there is a growing attempt to use PDL to reverse diabetes, knowledge of the effects of 
PDL on the islet as a whole may be crucial to the development of this technique as a 
therapeutic strategy for DM. 
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2. LITERATURE REVIEW 
2.1 THE ISLETS OF LANGERHANS 
2.1.1 Islet formation 
The pancreas develops as two evaginations of the endodermal lining of the primitive foregut 
(Edlund 1998, Gittes 2009, Sadler, Langman 2012, Romer, Sussel 2015). These evaginations 
into the surrounding mesoderm give rise to a dorsal pancreatic bud and a ventral pancreatic 
bud (Figure 1.A) (Gittes 2009, Matveyenko, Vella 2015). As the duodenum (part of the 
primitive foregut) undergoes rotation to assume its final C-shaped position, the ventral bud 
moves dorsally to come to lie inferior to the dorsal pancreatic bud (Sadler, Langman 2012). 
Subsequently, the two pancreatic buds fuse, forming one gland posterior to the stomach, 
between the duodenum and spleen (Figure 1B) (Sadler, Langman 2012). 
 
 
Figure 2.1. Development of the human pancreas.  A: Development of the ventral and dorsal pancreatic 
buds. B: Final position of the ventral pancreatic bud and fusion of the dorsal and ventral pancreatic 
buds. (Sadler, Langman 2012). 
During the early stages of development pro-pancreatic epithelium of the dorsal pancreatic bud 
is influenced by molecular signals from the notochord and endothelium of the dorsal aorta 
(Gittes 2009). The ventral pancreatic bud, however, is influenced by signals from the 
cardiogenic mesenchyme (Gittes 2009). Within the two buds the pro-pancreatic epithelial 
B 
A 
A 
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cells proliferate, branch and differentiate to form both the exocrine (acinar and ductal) and the 
endocrine (islet) tissues of the adult pancreas (Edlund 1998).  
In both the ventral and dorsal buds epithelial-mesenchymal interactions are important for 
normal pancreatic development (Gittes 2009, Marquez-Aguirre, Canales-Aguirre et al. 2015).  
Mesenchymal factors, including follistatin, promote development of the exocrine tissues of 
the pancreas (Miralles, Czernichow et al. 1998). Concomitantly, these mesenchymal factors 
repress pro-endocrine molecular signals, such as activin produced by the notochord (Miralles, 
Czernichow et al. 1998).  
Apart from the external molecular signals, many developmental studies have focused on 
elucidating the dynamic sequential expression of various transcription factors (TFs) within 
pancreatic progenitors leading to differentiation into the various pancreatic cell types 
(Neubuser et al. 1997, Edlund 1998, Li et al. 1999, Apelqvist, Gradwohl, Dierich et al. 2000, 
Sander, Sussel et al. 2000, Gu, Dubauskaite et al. 2002a, Hald, Hjorth et al. 2003, Collombat, 
Mansouri et al. 2003, Sander, Nishimura, Kondo et al. 2006, Sugiyama, Gu, Stein et al. 2010, 
Benitez et al. 2013,). Pancreatic and duodenal homeobox 1 (Pdx1) is the first TF expressed in 
progenitor cells indicating their commitment to develop to pancreatic cell types (Edlund 1998, 
Romer, Sussel 2015); this includes all acinar, ductal and islet cells of the pancreas (Gu, 
Dubauskaite et al. 2002b, Romer, Sussel 2015, Marquez-Aguirre, Canales-Aguirre et al. 
2015).  
The differential expression of the TF neurogenin 3 (Ngn3) determines whether progenitor 
cells will commit to an endocrine or exocrine cell fate, Ngn3 positive cells being endocrine 
progenitors ( Apelqvist, Li et al. 1999, Gradwohl, Dierich et al. 2000, Gu, Dubauskaite et al. 
2002b, Marquez-Aguirre, Canales-Aguirre et al. 2015). In pancreata where all Pdx1 
expressing cells are manipulated to express Ngn3, exocrine cell formation is inhibited and the 
pancreatic mass consists mainly of endocrine cells (Apelqvist, Li et al. 1999). The opposite is 
seen in pancreata where Ngn3 expression is blocked; in this instance, no differentiating 
endocrine progenitors are observed and none of the four endocrine cell types develop 
(Gradwohl, Dierich et al. 2000).  
Ngn3 expression is said to be regulated by the Notch signalling pathway (Apelqvist, Li et al. 
1999, Hald, Hjorth et al. 2003, Gittes 2009, Marquez-Aguirre, Canales-Aguirre et al. 2015). 
Activation of the notch signalling pathway prevents pro-pancreatic cells from terminally 
differentiating, blocking both exocrine and endocrine development (Hald, Hjorth et al. 2003). 
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Endocrine development is prevented as the Notch pathway upregulates expression of 
hairy/enhancer of split 1 (HES1), which in turn inhibits Ngn3 expression (Apelqvist, Li et al. 
1999). When Ngn3 expression is inhibited in pro-pancreatic cells, these cells will differentiate 
to exocrine cell types, following the expression of pro-exocrine TFs (Gradwohl, Dierich et al. 
2000). In endocrine progenitor cells, inhibition of Notch signalling allows for Ngn3 
expression. Ngn3 expression will result in a cascade of endocrine TF expression and will 
determine whether the progenitor will develop into a beta cell, alpha cell, delta cell or 
pancreatic polypeptide (PP) cell in the islet of Langerhans. Since the pro-endocrine TFs lie 
downstream from Ngn3, Ngn3 expression is essential to initiate endocrine development 
(Gradwohl, Dierich et al. 2000, Sugiyama, Benitez et al. 2013). 
One of the direct downstream targets of Ngn3 is the Neuronal Differentiation (NeuroD) TF 
(Gittes 2009, Sugiyama, Benitez et al. 2013). While expressed in all endocrine progenitors 
(Gradwohl, Dierich et al. 2000), NeuroD is specifically important in beta cells for beta cell 
function, expression of the insulin 1 gene and for maintaining beta cell maturity (Gu, Stein et 
al. 2010). Similarly, the pro-endocrine TF paired box 6 (Pax6) is expressed in all endocrine 
progenitors and plays a role in endocrine cell formation, hormone expression and 
development of islet architecture (Sander, Neubuser et al. 1997, Gittes 2009,).  
Initially endocrine progenitors also express both Aristaless related homeobox (Arx) and 
paired homeobox 4 (Pax4), before one TF subsequently becomes predominant (Collombat, 
Mansouri et al. 2003). Arx and Pax4 form a pair of pro-endocrine TFs important for proper 
development of endocrine progenitors into the four different islet cell types (Gittes 2009, 
Collombat, Mansouri et al. 2003). If Arx expression becomes predominant, the formation of 
alpha cells is promoted, while beta and delta cell formation is promoted when Pax4 
expression becomes predominant (Collombat, Mansouri et al. 2003).  
Other important endocrine TFs include the homeobox proteins Nkx2.2 and Nkx6.1, as well as 
the Musculoaponeurotic Fibrosarcoma Oncogene homologs A and B (MafA and MafB). In 
mice with a deleted Nkx2.2 gene, none of the islet cells express any hormones; indicating the 
importance of Nkx2.2 in the formation of mature and functional islet cells (Sander, Sussel et 
al. 2000). Nkx6.1, another TF that regulates hormone expression, lies downstream from 
Nkx2.2 and is important in beta cell development (Sander, Sussel et al. 2000). As the beta 
cells develop, Pdx1 is again expressed and is seen to be co-expressed with Nkx6.1 (Sander, 
Sussel et al. 2000). Upregulation of Pdx1 expression in developing beta cells is associated 
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with switching expression of the TF MafB to the TF MafA; MafA being expressed in mature 
beta cells while MafB is expressed in mature alpha cells (Nishimura, Kondo et al. 2006). As 
recently reviewed, the interactions between TFs and how exactly they induce specification of 
islet cell types has not been elucidated (Romer, Sussel 2015). It is, however, clear that a 
normal sequence of TF expression during islet development is crucial for the formation of 
functional islets with the proper composition and architecture. 
2.1.2 Islet composition and architecture 
As stated earlier, the islets of Langerhans consist of four endocrine cell types, the beta cells 
(secreting insulin), alpha cells (secreting glucagon), delta cells (secreting somatostatin) and 
PP cells (secreting pancreatic polypeptide) (Steiner, Kim et al. 2010). The relative amount of 
each cell type per islet is described as islet composition, while islet architecture describes the 
location of each cell type within the islet (Steiner, Kim et al. 2010). Islet composition and 
architecture may vary between the different parts of the pancreas and between islets of 
different species (Kim, Miller et al. 2009, Steiner, Kim et al. 2010).  
2.1.2.1 Human islets 
Human islets of Langerhans have been described as consisting of approximately 53.9% beta 
cells, 34.4% alpha cells, 10.4% delta cells and few (1.3%) PP cells (Figure 2.2) (Brissova, 
Fowler et al. 2005, Steiner, Kim et al. 2010). The exact composition of the islets may, 
however, vary between different regions in the human pancreas – for example the uncinate 
process and head of the pancreas have been indicated as PP cell rich areas (Gersell, Gingerich 
et al. 1979). Gersell et al. (1979) reports that beta and alpha cells are more abundant within 
islets of the tail of the pancreas compared to the islets of the head of the pancreas. 
Contradictory findings indicate that islet composition may be similar in the different areas of 
the pancreas, except for alpha cells being more numerous in islets of the neck of the pancreas 
(Cabrera, Berman et al. 2006). Islet composition may also vary between islets within the same 
area of the pancreas (Cabrera, Berman et al. 2006). When comparing human islet composition 
to that of other species (monkey, pig, rabbit, mouse and bird), human islets generally have a 
smaller fraction of beta cells (Kim, Miller et al. 2009).  
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Figure 2.2. Schematic representation of the human islet of Langerhans. beta cells (green); alpha cells 
(red); delta cells (blue). PP cells are not shown. (Adapted from Steiner, Kim et al. 2010). 
Human islets also differ from those of other species in terms of islet architecture (Kim, Miller 
et al. 2009, Steiner, Kim et al. 2010). A study conducted by Erlandsen et al. (1976) described 
human islets as being lobulated and noted that the observed lobules contained central beta cell 
clusters surrounded by alpha, delta and PP cells. However, other studies describe the islets as 
being randomly arranged (Figure 2.2), with no cluster of beta cells and all endocrine cell types 
dispersed throughout the islet (Brissova, Fowler et al. 2005, Cabrera, Berman et al. 2006). 
Moreover, different architectures for small and large islets have been reported (Bosco, 
Armanet et al. 2010, Farhat, Almelkar et al. 2013). In these models, small human islets have a 
central core of beta cells surrounded by a mantle of non-beta cells (Bosco, Armanet et al. 
2010, Farhat, Almelkar et al. 2013), while in larger islets, non-beta cells are more frequently 
observed within the core of islets (Bosco, Armanet et al. 2010) and the endocrine cell types 
are evenly dispersed (Farhat, Almelkar et al. 2013). Furthermore, Bosco et al. (2010) 
proposed that the endocrine cells of the islets are arranged into a folded trilaminar epithelial 
plate, where a central layer of beta cells is bordered on each side by non-beta cells. 
2.1.2.2 Rodent islets 
The composition and architecture of rodent islets of Langerhans have also been extensively 
described in the literature (Erlandsen, Hegre et al. 1976, Weiczoreck, Pospischil et al. 1998, 
Esni, Taljedal et al. 1999, Zafar, Mughal 2002, Brissova, Fowler et al. 2005, Cabrera, Berman 
et al. 2006, Steiner, Kim et al. 2010). Rat and mice islets are composed 60-85% beta cells, 15-
25% alpha cells, 6-10% delta cells and less than 1% PP cells (Figure 2.3) (Erlandsen, Hegre et 
al. 1976, Weiczoreck, Pospischil et al. 1998, Brissova, Fowler et al. 2005, Steiner, Kim et al. 
2010) . As in humans, the composition of rodent islets may also vary in different parts of the 
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pancreas. In albino rats, it was found that alpha cells are more abundant in the head area of the 
pancreas than in the tail, while beta cells and delta cells are more abundant in the tail area than 
in the head of the pancreas (Zafar, Mughal 2002). PP cells are reported to be relatively more 
abundant in what some authors describe as the lower duodenal (head) area of the pancreas 
(Elayat, El-Naggar et al. 1995). When comparing the islet composition of mice and human 
islets, mice islets generally have a higher fraction of beta cells than human islets, while alpha 
cells are more abundant in human islets (Cabrera, Berman et al. 2006).  
 
 
Figure 2.3. Schematic representation of the rodent islet of Langerhans. beta cells (green); alpha cells 
(red); delta cells (blue). PP cells are not shown. (Adapted from Steiner, Kim et al. 2010). 
With regards to the architecture, rodent islets are consistently described in the literature as 
having a central core of beta cells surrounded by non-beta cells (Figure 2.3) (Erlandsen, 
Hegre et al. 1976, Elayat, El-Naggar et al. 1995, Weiczoreck, Pospischil et al. 1998, 
Weiczoreck, Pospischil et al. 1998, Esni, Taljedal et al. 1999, Zafar, Mughal 2002, Brissova, 
Fowler et al. 2005, Cabrera, Berman et al. 2006, Kim, Miller et al. 2009). The mantle consists 
mainly of alpha cells, with some delta cells that are located either in the periphery of the 
islets, between alpha cells or intermediately between alpha and beta cells (Erlandsen, Hegre et 
al. 1976, Zafar, Mughal 2002). PP cells are located at the periphery of rodent islets and are 
observed as isolated cells or small clusters (Erlandsen, Hegre et al. 1976, Elayat, El-Naggar et 
al. 1995). Research suggests that the segregation of the different cell types within the islets of 
Langherhans may be governed by cell adhesion molecules (CAM’s), especially neural cell 
adhesion molecules (N-CAM) (Esni, Taljedal et al. 1999). Since the different islet cell types 
may be segregated within the islet, the pattern of islet perfusion may play an important role in 
intercellular communication within the islets (Brunicardi, Stagner et al. 1996).  
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2.1.3 Microvasculature within the islets 
Three different models of islet perfusion (Figure 2.4) were summarized in a review of islet 
microcirculation published in 1996 (Brunicardi, Stagner et al. 1996). These models include: 
1) a model where non-beta cells are perfused before beta cells, 2) a model where beta cells are 
perfused before non-beta cells and 3) a model where islets are perfused from one pole to 
another (Brunicardi, Stagner et al. 1996, Ballian, Brunicardi 2007). When these models were 
again reviewed in 2007 more debate was created (Ballian, Brunicardi 2007). 
 
 
Figure 2.4. The three models of islet microcirculation  A: Model 1, non-beta cells perfused before beta 
cells; B: Model 2, beta cells perfused before non-beta cells; C: Model 3, Islet perfusion from one pole 
to the other. Key: (A) alpha cells; (Art) arteriole; (B) beta cells; (D) delta cells; (F) PP cells; (V) 
venule. (Adapted from Brunicardi, Stagner et al. 1996). 
In model 1 (Figure 2.4A), the technique of corrosion casting in combination with scanning 
electron microscopy was largely used to allow visualization of the islet vasculature. Studies in 
support of this model describe an insular arteriole that supplies arterial blood to the islets 
(Murakami, Miyake et al. 1997, Ohtani, Wang 1997). In rats, rabbits and mice this afferent 
vessel ends in the mantle region of the islet (where non-beta cells are located); here it 
branches to form a primary capillary network in the mantle layer that will again branch to 
form a secondary capillary plexus in the core of the islet (Fujita et al. 1993, Murakami, 
Miyake et al. 1997, Ohtani, Wang 1997, Murakami). Experiments in rats, where the 
vasculature was incompletely injected with the casting medium, indicated that the capillary 
plexus of the mantle layer of the islet was filled prior to the core capillary plexus (Murakami, 
Miyake et al. 1997). 
In the islets of Formosan monkeys, where alpha and delta cells form the core of the islet with 
beta cells in the periphery, perfusion was found to occur from the core to the mantle of the 
islet (Murakami, Fujita et al. 1993). These results indicate that even when islet architecture 
differs between species, islet perfusion may follow the same pattern where non-beta cells are 
perfused before beta cells. The implication of this model of islet microcirculation would be 
that beta cell function is regulated by the hormones secreted by the non-beta cells (Murakami, 
A B C 
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Fujita et al. 1993, Murakami, Miyake et al. 1997). It is, however, generally accepted by 
authors that there is a plausible flow of blood within the islet from the mantle to the core and 
back to the mantle ( Fujita et al. 1993, Ohtani, Wang 1997, Murakami), indicating that intra-
islet communication via the microcirculation may be more intricate than what is proposed by 
model 1.  
In model 2 (Figure 2.4B) retrograde and anterograde islet perfusion techniques were mostly 
used. Anterograde perfusion is perfusion in the normal direction and retrograde perfusion is 
when the direction of perfusion is reversed. Experiments performed on rat, dog and human 
islets indicate that, during anterograde perfusion, the subsequent addition of an anti-insulin 
antibody into circulation causes the levels of glucagon and somatostatin to rise (Stagner, 
Samols 1986, Samols, Stagner et al. 1988, Stagner, Samols 1992), while in retrograde 
perfusion, the subsequent addition of an anti-insulin antibody does not change glucagon and 
somatostatin levels (Stagner, Samols 1986, Samols, Stagner et al. 1988, Stagner, Samols 
1992).  The addition of the anti-insulin antibody would only change glucagon and 
somatostatin levels when the direction of perfusion was such that alpha cells and delta cells 
were exposed to insulin prior to addition of the antibody. Consequently, during anterograde 
perfusion, alpha and delta cells are exposed to insulin. It was therefore concluded that in rats, 
dogs and humans, beta cells are perfused before non-beta cells (Stagner, Samols 1986, 
Samols, Stagner et al. 1988, Stagner, Samols 1992).  
Experiments with retrograde and anterograde infusion of glucose, insulin, glucagon and 
somatostatin confirmed these results (Stagner, Samols 1986, Stagner, Samols et al. 1988). 
Interestingly, an early corrosion cast experiment performed on rat islets also supports this 
model of islet perfusion. This study found that afferent arterioles enter the islet in areas where 
the non-beta cell mantle is discontinuous and then branch to form a capillary network within 
the beta cell core (Bonner-Weir, Orci 1982). An immunohistochemical analysis of islet 
microcirculation also describes this perfusion pattern in the rat (Weiczoreck, Pospischil et al. 
1998). 
The third model (Figure 2.4C), proposing that blood flow through the islet may be polar, 
describes a more complex microcirculation pattern within the islet. Liu et al. (1993) used 
fluorescence video-microscopy to dynamically evaluate islet perfusion. It was observed that 
the arteriole supplying the islet branches into a capillary network within the mantle layer of 
one hemisphere of the islet, blood then fills the mantle layer, followed by the core of that 
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hemisphere of the islet (Liu, Guth et al. 1993). Thereafter, blood would first fill the core and 
then the mantle of the opposite hemisphere of the islet (Liu, Guth et al. 1993). Furthermore, 
microsphere injection into the islet microvasculature indicated that the route of a single red 
blood cell is torturous though the capillary network and that blood may also flow from the 
mantle to the core and back to the mantle within the same hemisphere; therefore, perfusion in 
the islet may not follow a strictly polar route (Liu, Guth et al. 1993).  
A more recent study, conducted on mice pancreatic islets, revealed that within the same 
pancreas different perfusion patterns may be found. The majority of the islets displayed 
perfusion from the core to the mantle (model 2), but 35% of islets had a polar perfusion 
pattern (Nyman, Wells et al. 2008). Authors supporting a model of a more complex or 
dynamic perfusion pattern in the islets of Langerhans also argue that, since there is variation 
in islet architecture within the same animal, the relationship between islet architecture and 
perfusion may not be as simple as proposed by model 1 and model 2 (Kim, Miller et al. 
2009). For example, in human islets different architectures are reported for small and large 
islets. In large islets beta cells less frequently have direct contact to blood vessels than in 
smaller islets (Farhat, Almelkar et al. 2013). In another study on human islets different 
endocrine cell types are seen randomly arranged along the blood vessels (Cabrera, Berman et 
al. 2006). For example, a beta cell may be bordered by an alpha cell or delta cell on either 
side along the blood vessel or found to face non-beta cells located on the opposite side of the 
blood vessel (Cabrera, Berman et al. 2006). This random arrangement of cells along the 
capillaries indicates that there may be no specific order in cellular perfusion within the human 
islets of Langerhans. 
Venous drainage is not described in detail in model 2 and model 3. However, studies 
supporting model 1 propose that islets are drained by three different efferent vessels: 1) 
insulo-portal vessels that drain blood from the islet capillary plexus to the acinar capillary 
plexus, 2) emissary venules that drain blood from the islet directly to the systemic circulation 
and 3) insulo-ductal portal vessels that drain blood from the islets to the periductal plexuses 
(Ohtani, Wang 1997). The venous drainage of the islet depends on the islet’s position within 
the pancreas; islets may be intralobular (within an acinar lobule), interlobular (between acinar 
lobules) or periductal (close to pancreatic ducts) (Ohtani, Wang 1997).  
In the rat and guinea pig, small intralobular islets have insulo-acinar portal vessels, while 
larger intralobular islets would, in addition to insulo-acinar portal vessels, also have emissary 
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veins (Ohtani, Wang 1997). Interlobular islets are reported to have both emissary and insulo-
acinar portal vessels, whereas periductal islets would (in addition to these two vessels) also 
have insulo-ductal portal vessels (Ohtani, Wang 1997). Incomplete injection of casting 
medium into the islet vasculature has shown that islets are drained via their insulo-acinar 
portal vessels first, before being drained by additional emissary vessels (Murakami, Miyake et 
al. 1997).  
Of the three distinct models of islet perfusion described in the literature, to date, no model has 
been proven to be superior to the other, neither has a model been proven to be invalid. On the 
contrary, more than one model of perfusion has been observed within the same animal 
(Nyman, Wells et al. 2008). Regardless of the model of perfusion supported by different 
studies, it is generally agreed that islets are highly vascularized and that islet perfusion has 
important implications for islet function. 
2.1.4 Islet function and mechanism of action of cell component 
The islets of Langerhans mainly function to maintain blood glucose homeostasis via the 
hormones insulin and glucagon. Insulin is responsible for decreasing blood glucose levels 
after a meal when blood glucose levels rise. The increased concentration of circulating 
glucose is the primary stimulus initiating insulin release from beta cells by means of an 
excitation-secretion process (Matschinsky, Ellerman 1967, Pralong, Bartley et al. 1990, 
Aspinwall, Lakey et al. 1999, Rorsman, Eliasson et al. 2000, Sherwood 2010). Rising glucose 
levels cause more glucose to enter the beta cell (via the GLUT-2 transporter) and glucose is 
subsequently metabolised to ATP; ATP in turn triggers depolarization of the beta cell causing 
calcium to enter the cell and promote insulin exocytosis (Matschinsky, Ellerman 1967, 
Pralong, Bartley et al. 1990, Rorsman, Eliasson et al. 2000, Sherwood 2010). Insulin action 
triggers the uptake of glucose, fatty acids and amino acids from the blood by targeting the 
liver, skeletal muscles and adipocytes. Concomitantly insulin stimulates metabolic pathways 
for the utilization of glucose, storage of carbohydrates and fat, and for protein synthesis 
(Sherwood 2010). 
The effects of insulin are opposed by glucagon, secreted from the pancreatic alpha cells 
between meals when blood glucose levels are low (Jiang, Zhang 2003, Sherwood 2010). 
Glucagon mainly targets the liver where it acts via the cAMP second messenger pathway to 
increase hepatic glucose production by stimulating glycogenolysis and gluconeogenesis 
(Jiang, Zhang 2003, Sherwood 2010). Concomitantly, glucagon prevents the storage of 
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glucose by inhibiting glycogen synthase, ultimately resulting in an increase in blood glucose 
levels (Ezrin, Salter et al. 1958, Jiang, Zhang 2003, Sherwood 2010). Other catabolic effects 
of glucagon include increasing breakdown of fat, thereby increasing serum free fatty acid 
levels, and hepatic protein degradation (Pontiroli, Perfetti et al. 1993, Sherwood 2010,). 
Contrary to the actions of insulin and glucagon, islet somatostatin does not influence glucose 
homeostasis by acting on peripheral body tissues (Cherrington, Caldwell et al. 1977). 
Somatostatin does, however, influence glucose homeostasis by its inhibitory paracrine effects 
on both insulin and glucagon secretion (Hauge-Evans, King et al. 2009). Insulin and glucagon 
secretagogues concomitantly stimulate delta cells to release somatostatin that will limit the 
beta and alpha cell’s response to the stimulus (Hauge-Evans, King et al. 2009).  There are 
several different subtypes of somatostatin receptors (SSTRs) that are expressed by beta and 
alpha cells for somatostatin, where SSTR2 is regarded as the main mediator of somatostatin 
induced inhibition of insulin and glucagon secretion in humans (Reubi, Kappeler et al. 1998, 
Ludvigsen, Olsson et al. 2004, Singh, Brendel et al. 2007, Kailey, van de Bunt et al. 2012). 
Somatostatin specifically inhibits insulin secretion by hyperpolarizing and preventing calcium 
influx into the beta cell and by directly preventing insulin exocytosis (Kailey, van de Bunt et 
al. 2012).  
The fourth islet hormone, pancreatic polypeptide (PP), also influences energy balance via its 
effects on peripheral tissues. This peptide hormone is secreted by the PP cells in response to 
food intake, specifically the digestion of lipids in the duodenum (Feinle-Bisset, Patterson et 
al. 2005). It is interesting to note that PP cells are not stimulated by nutrients in the blood 
stream (Adrian, Bloom et al. 1977) as is the case with stimulation of the other three islet cell 
types. PP functions to decrease food intake (Ueno, Inui et al. 1999, Asakawa, Inui et al. 2003, 
Batterham, Le Roux et al. 2003, Jesudason, Monteiro et al. 2007) and slows the rate of gastric 
emptying (Ueno, Inui et al. 1999, Asakawa, Inui et al. 2003, Schmidt, Naslund et al. 2005). 
This is achieved by PP’s inhibitory effects on vagus nerve activity, hypothalamic feeding-
stimulating protein expression and ghrelin release in the stomach (Asakawa, Inui et al. 2003, 
Kojima, Ueno et al. 2007).  
The release and function of each islet hormone should, however, not be viewed in isolation; 
islet composition and architecture form critical components of whole islet function. This is 
evident when considering islet somatostatin that mainly has a paracrine influence within the 
islet, allowing the fine-tuning of beta and alpha cell responses to fluctuating blood glucose 
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levels (Hauge-Evans, King et al. 2009). Furthermore, a two-way interaction between beta and 
alpha cells is reported to influence both insulin and glucagon secretion (Ishihara, Maechler et 
al. 2003, Franklin, Gromada et al. 2005, Wang, Zhang et al. 2011). Glucagon secreted by 
alpha cells allows for increased glucose stimulated insulin release by beta cells (Wang, Zhang 
et al. 2011), while insulin and zinc secreted from beta cells inhibit glucagon secretion 
(Ishihara, Maechler et al. 2003, Franklin, Gromada et al. 2005).  
A study on the paracrine relationships between the cells of the islets proposed the following 
regulatory relationships within the islet: 1) beta cell secretion inhibits glucagon release from 
alpha cells, 2) alpha cell secretion stimulates beta cell and delta cell secretion and 3) 
somatostatin release inhibits secretion from beta, alpha and PP cells (Weir, Samols et al. 
1979). It is, therefore, important for islet function that the islets are composed of the correct 
amounts of each cell type. Apart from paracrine interactions within the islet, morphological 
studies indicate the presence of gap junctions and direct communicating pathways between 
homologous and heterologous groups of endocrine cells within the islet (Orci, Malaisse-Lagae 
et al. 1975, Meda, Kohen et al. 1982).  
In rodent islets, gap junctions allow for synchronous intracellular calcium oscillations 
(electrical coupling) throughout the beta cell population of the islet (Benninger, Head et al. 
2011). Electrical coupling may be important for beta cell function as the beta cells within an 
islet are heterogeneous in terms of their excitability. At sub-threshold glucose levels, gap 
junctions appear to allow the less-excitable beta cells to supress increased intracellular 
calcium levels in the more-excitable beta cells, and the islet beta cell population then responds 
with uniform electrical activity (Benninger, Head et al. 2011). While gap junctions do not 
function to directly stimulate or supress insulin release, dissociated beta cells are observed to 
display increased insulin release at sub-threshold glucose levels and, therefore, it can be 
argued that other cellular adhesion molecules are important in regulating insulin secretion 
(Benninger, Head et al. 2011).  
A more recent study contradicts these findings stating that, while beta cells are electrically 
coupled, gap junctions do not mediate the flow of calcium between beta cells when one beta 
cell is stimulated (Stozer, Gosak et al. 2013). However, the authors do agree that beta cell 
functional activity is synchronized and that the structure of the islet may play an important 
role in this synchronization (Stozer, Gosak et al. 2013). Apart from physical connections 
between cells, insulin itself has also been indicated to regulate (stimulate) insulin release 
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independent of intracellular calcium levels; this autocrine effect was proposed to explain why 
clusters of beta cells are able to secrete more insulin than isolated beta cells when stimulated 
by glucose (Aspinwall, Lakey et al. 1999).  
In both human and rodent islets, it was found that small islets (less than 150 µm or 125 µm in 
diameter) secrete more insulin than large islets (MacGregor, Williams et al. 2006, Lehmann, 
Zuellig et al. 2007, Fujita, Takita et al. 2011, Huang, Novikova et al. 2011, Farhat, Almelkar 
et al. 2013), indicating that the size of the islet also has implications for beta cell function. 
This phenomenon may be due to beta cells within the small islets having a higher insulin 
content than those found in large islets (Huang, Novikova et al. 2011, Farhat, Almelkar et al. 
2013). Another explanation could be a difference in the composition of small and large islets. 
Studies on human islets reported a larger beta cell fraction in small islets as compared to large 
islets (Lehmann, Zuellig et al. 2007, Farhat, Almelkar et al. 2013), but no compositional 
difference was observed in rodent islets (Huang, Novikova et al. 2011).  A study on rodents 
did, however, indicate increased endocrine cell density in small islets that could account for 
increased insulin release from small islets (Huang, Novikova et al. 2011).  
Farhat et al. (2013) also proposed that, in human islets, the different architectures of small and 
large islets may influence beta cell function. Therefore, the clustering of beta cells in the core 
of small islets may favour beta cell insulin secretion. The superior functioning of small islets 
is also emphasised in clinical and experimental islet transplantation studies. In this context, 
cells within small islets are found to be more viable after isolation from a donor and small 
islets also have better transplantation outcomes than larger islets (MacGregor, Williams et al. 
2006, Lehmann, Zuellig et al. 2007). In general, better transplantation outcomes are obtained 
when transplanting morphologically intact islets compared to pelleted islets (Rackham, Jones 
et al. 2013).  
Similarly, Cabrera et al. (2006) also noted the effect of islet architecture on beta cell function. 
The authors compared human and rodent islet responses to glucose stimulation and found that 
human islets (where beta cells are dispersed) did not respond to glucose with synchronous 
intracellular calcium oscillations (Cabrera, Berman et al. 2006). This is in contrast to findings 
in rodent islets where all islet beta cells responded to glucose with synchronous intracellular 
calcium oscillations, as beta cells were clustered within the core of the islet (Cabrera, Berman 
et al. 2006).  
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Furthermore, Shiota et al. (2013) found that alpha cell deficient rodent islets can have normal 
beta cell function, while Wang et al. (2011) reported that alpha cell deficient human islets had 
impaired beta cell function. Together, these findings support the view that compositional 
differences between human and rodent islets may also have an impact on islet function.  
Based on the above, alpha cells may therefore have a stronger regulatory role in human islets, 
possibly because alpha cells are more numerous in human islets; this view was previously 
proposed by Cabrera et al. (Cabrera, Berman et al. 2006). 
From the discussion above, it is clear that the islets of Langerhans are important endocrine 
micro-organs. Islet composition and architecture are integral to islet function as demonstrated 
by pathological conditions such as DM that result from a disruption in islet composition. 
2.2 CHANGES IN ISLET COMPOSITION AND ARCHITECTURE 
2.2.1 Pathological changes in the islet 
The malfunction of insulin secretion by beta cells results in hyperglycaemia which is a 
characteristic of both type 1 and type 2 DM (Sherwood 2010). In Type 1 DM (T1DM), a lack 
of insulin secretion is due to the autoimmune destruction of the pancreatic beta cells 
(Sherwood 2010, Atkinson 2000). In this instance, beta cells, which are the most abundant 
cell type within the islet, are damaged and lost from the islets, thereby disrupting the islet 
composition. Patients with T1DM have increased postprandial blood glucose levels (BGL) 
and decreased insulin response resulting from the pathological change in islet composition 
(Greenbaum, Prigeon et al. 2002, Heptulla, Rodriguez et al. 2005). In addition to the lack of 
insulin, beta cell deficiency also results in the unregulated secretion of glucagon from the 
alpha cells. In T1DM patients, there is no suppression of glucagon secretion following a meal 
(Greenbaum, Prigeon et al. 2002, Heptulla, Rodriguez et al. 2005), therefore worsening 
postprandial hyperglycaemia as hepatic glucose output is continuously stimulated. While 
T1DM is managed by exogenous insulin administration, research indicates that insulin pump 
therapy is not sufficient to control postprandial hyperglycaemia (Heptulla, Rodriguez et al. 
2005), highlighting the importance of intra-islet insulin and beta cell function.  
In type 2 DM (T2DM) beta cells still produce insulin, but peripheral body tissues become 
resistant to the insulin (Sherwood 2010). Moreover, loss of beta cells from the islet has been 
reported in patients with T2DM (Kilimnik, Zhao et al. 2011), implicating a change in islet 
composition in the pathophysiology of T2DM. An excessive appetite overworks the beta 
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cells, which leads to their death. This loss of beta cells from pancreatic islets is widely 
reported (Janson et al. 2003, Kilimnik, Zhao et al. 2011, Butler, Henquin, Rahier 2011, 
Jurgens, Toukatly et al. 2011). The destruction of beta cells may occur via apoptosis 
associated with the deposition of amyloid, which is characteristic of the islets of T2DM 
patients (Butler, Janson et al. 2003, Jurgens, Toukatly et al. 2011). As with T1DM, the loss of 
beta cells from the islets results in hyperglucagonemia; this unregulated glucagon secretion 
has been directly linked to decreased insulin pulse mass in T2DM (Menge, Gruber et al. 
2011). The importance of islet composition is repeatedly emphasised by studies on both 
T1DM and T2DM and even more so by studies on experimentally induced diabetes in animal 
models. 
In experimental studies, diabetes can be chemically induced using the beta-cytotoxic agents 
streptozotocin (STZ) or alloxan (Kjems, Kirby et al. 2001, Mythili, Vyas et al. 2004, Meier, 
Kjems et al. 2006). These beta-cytotoxic agents primarily cause destruction of the pancreatic 
beta cells, while other islet cells remain unaffected (except at higher doses where damage may 
occur to the alpha cells) (Kjems, Kirby et al. 2001, Mythili, Vyas et al. 2004, Meier, Kjems et 
al. 2006). Selective chemical destruction of islet beta cells results in a hyperglycaemic 
phenotype (Mythili, Vyas et al. 2004), as is characteristic of human diabetes. Chemically 
induced diabetic animals display postprandial hyperglycaemia, decreased insulin response and 
hyperglucagonemia (Kjems, Kirby et al. 2001, Meier, Kjems et al. 2006, Meier, Ueberberg et 
al. 2011).  
From the experimental models, it could be determined that even when 25% of the islet beta 
cells survive, glucose-induced insulin secretion is non-existent (Meier, Ueberberg et al. 2011). 
This indicates disproportionate changes in islet composition as integral to the pathophysiology 
of diabetes. Furthermore, administration of exogenous insulin in a diabetic model could not 
reverse the diabetic phenotype (Meier, Ueberberg et al. 2011). This provides evidence that 
endogenous beta cell function, whether it is locally released insulin or another beta cell 
secretory product, such as zinc (Ishihara, Maechler et al. 2003, Franklin, Gromada et al. 
2005), is critical for the normal functioning of islets as a whole (Meier, Ueberberg et al. 
2011).  
Normoglycemia could, however, be obtained in diabetic animals without insulin 
administration, when reversing hyperglucagonemia (Yu, Park et al. 2008). Moreover, 
glucagon receptor knockout mice treated with STZ remained normoglycemic despite beta cell 
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destruction (Lee, Wang et al. 2011b). These findings indicate that unregulated alpha cell 
secretion in islets with beta cell deficiency may be a key contributor to the pathological 
hyperglycaemic phenotype characteristic of DM.  
Since normal islet composition is essential for blood glucose homeostasis, therapeutic 
strategies that aim to reverse diabetes would either have to replace diabetic islets by the 
transplantation of morphologically intact islets, or these strategies should find ways of 
manipulating islet plasticity to allow restoration of normal islet morphology. Islet plasticity 
refers to the ability of the islet to adapt morphologically to meet the physiological needs of the 
organism or in response to injury (Hanley, Austin et al. 2010, Jacovetti, Abderrahmani et al. 
2012, Saisho, Butler et al. 2013, Nollevaux, Rahier et al. 2013, Bramswig, Everett et al. 
2013). Experimental models of pancreatic injury, such as pancreatic duct ligation, have been 
investigated as a means of manipulating adult islet plasticity. 
2.2.2 Adult islet plasticity 
Human beta cell mass remains relatively constant under normal physiological conditions, 
between the ages 20 and 100 (Saisho, Butler et al. 2013), however, beta cell mass is not static. 
Conditions such as obesity, that result in an increase in insulin demand, are associated with 
increased beta cell mass (Hanley, Austin et al. 2010, Saisho, Butler et al. 2013). This increase 
is the result of an increase in the number of pancreatic beta cells and not the size of beta cells 
(Saisho, Butler et al. 2013). Increased beta cell mass is also associated with pregnancy and it 
is thought that micro-RNAs that influence beta cell replication and survival are responsible 
for the adaptive beta cell expansion during pregnancy and obesity (Jacovetti, Abderrahmani et 
al. 2012). If the mechanisms responsible for this adaptive increase in beta cell mass fail, 
T2DM may develop (Hanley, Austin et al. 2010). Therefore, the understanding of pancreatic 
plasticity is an important step in finding new treatment strategies for DM, where the first step 
could be to identify cellular sources from which new beta cells can be formed (Marquez-
Aguirre, Canales-Aguirre et al. 2015). 
2.2.2.1 Cellular sources of new beta cells in the adult pancreas 
Sources of new beta cells in the adult human pancreas are still largely unknown (Saisho, 
Butler et al. 2013). Experimental in vivo and in vitro studies investigating beta cell mass 
plasticity propose that new beta cells in the adult pancreas may originate from various sources 
including pre-existing beta cells (Dor, Brown et al. 2004, Georgia, Bhushan 2004, Nir, 
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Melton et al. 2007, Teta, Rankin et al. 2007, Meier, Butler et al. 2008, Nollevaux, Rahier et 
al. 2013), alpha cells (Collombat, Mansouri et al. 2003, Thorel, Nepote et al. 2010, Chung, 
Levine 2010, Bramswig, Everett et al. 2013), pancreatic duct cells (Zhou, Brown et al. 2008, 
Rukstalis et al. 2010, Miyashita, Criscimanna, Speicher et al. 2011, Swales, Martens et al. 
2012, Li, Miyatsuka et al. 2014), centroacinar duct cells (Nagasao, Yoshioka et al. 2003, 
Rovira, Scott et al. 2010, Tchokonte-Nana 2011), acinar cells (Collombat, Mansouri et al. 
2003, Thorel, Nepote et al. 2010, Chung, Hao et al. 2010, Bramswig, Everett et al. 2013) and 
mesenchymal stem cells (MSCs) (Sordi, Malosio et al. 2005, Moriscot, de Fraipont et al. 
2005, Shin et al. 2005, Timper, Seboek et al. 2006, Gao, Song et al. 2014, Choi). Knowledge 
of pancreatic islet plasticity is crucial for the development of a method that allows for the in 
vivo generation of beta cells as a novel treatment strategy for DM (Juhl, Bonner-Weir et al. 
2010). 
During normal beta cell mass expansion between birth and adulthood, beta cell replication is 
the most important source of new beta cells (Meier, Butler et al. 2008). Similarly, beta cell 
self-renewal appears to be the predominant mechanism of beta cell mass expansion during 
normal growth of mice pancreata (Dor, Brown et al. 2004, Georgia, Bhushan 2004, Teta, 
Rankin et al. 2007). Subsequently, the islets found in adult mice are all derived from islets 
already present during early adulthood (Dor, Brown et al. 2004). During normal growth, beta 
cell replication was identified as the mechanism by which new beta cells formed in mice 
following the ablation of a large amount of pre-existing beta cells, as well as after partial 
pancreatectomy (Dor, Brown et al. 2004, Nir, Melton et al. 2007, Nollevaux, Rahier et al. 
2013). Similarly, the formation of new beta cells during pregnancy occurs via replication of 
pre-existing beta cells (Teta, Rankin et al. 2007).  
Teta et al. (Teta, Rankin et al. 2007) proposed that beta cells have the ability to replicate more 
than once; however, serial replications are slowed during normal growth due to a replication 
refractory period. This refractory period may be overcome during conditions such as 
pregnancy (Teta, Rankin et al. 2007). Although these authors did not observe other cell types 
contributing significantly to beta cell formation, the possibility of alternative sources from 
which beta cells can be formed have not been ruled out. 
Islet alpha cells have been proposed as one such alternative source from which beta cells can 
be formed (Thorel, Nepote et al. 2010, Chung, Hao et al. 2010). In order to study the 
transdifferentiation of alpha cells in vivo, animal models were created where almost all pre-
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existing beta cells were destroyed; this was done by either using the β-cytotoxic chemical 
alloxan (Chung, Hao et al. 2010) or by selectively inducing expression of the diphtheria toxin 
receptor on beta cells (Thorel, Nepote et al. 2010). Following near total beta cell destruction, 
Chung et al. (2010) used pancreatic duct ligation (PDL) to induce beta cell regeneration, 
while Thorel et al. (2010) allowed for natural regeneration. In both sets of experiments it was 
concluded that the replication rate of the few remaining beta cells could not account for the 
total beta cell formation that was observed (Thorel, Nepote et al. 2010, Chung, Hao et al. 
2010). Upon further investigation, intermediate cells expressing both alpha and beta cell 
markers (for example glucagon and insulin, glucagon and Pdx1, and glucagon and Nkx6.1), 
indicated transdifferentiation of pancreatic alpha cells to beta cells (Thorel, Nepote et al. 
2010, Chung, Hao et al. 2010). This genetic reprogramming of alpha cells involves expression 
of the transcription factor Ngn3 (Collombat, Mansouri et al. 2003). An alpha-to-beta cell 
conversion has also been induced in transgenic mice by ectopic expression of the transcription 
factor Pax4 (Collombat, Mansouri et al. 2003). 
Human pancreatic alpha cells display a pattern of histone modification (an epigenetic 
modification) similar to that of human embryonic stem cells, indicating that there is a high 
degree of epigenetic plasticity in human alpha cells (Bramswig, Everett et al. 2013). When 
this pattern is disrupted, alpha cells may be partially converted to beta cells (Bramswig, 
Everett et al. 2013). These in vitro findings suggest that human alpha cells, similar to rodent 
alpha cells, may have the ability to transdifferentiate to beta cells in conditions of beta cell 
destruction (Chung, Hao et al. 2010, Bramswig, Everett et al. 2013).  
Another in vitro study on human islet plasticity, focused on duct cells as a source of new beta 
cells; these authors induced ectopic Ngn3 expression in duct cells and found that this could 
initiate transdifferentiation to a neuro-endocrine state (Swales, Martens et al. 2012). 
Therefore, human pancreatic duct cells also display some degree of plasticity. More recently, 
experiments inducing the expression of Pdx1 prior to Ngn3 and MafA promoted insulin 
expression in a ductal cell line (Miyashita, Miyatsuka et al. 2014). In vivo, transdifferentiation 
of duct cells to beta cells was observed in mice (Criscimanna, Speicher et al. 2011).  
Criscimanna et al. (2011) created a transgenic mouse model where selective expression of the 
diphtheria toxin receptor was used to destroy beta, alpha, acinar and some of the pancreatic 
duct cells. Both the endocrine and exocrine compartments of the pancreas regenerated within 
three to four weeks. In this model of severe injury, newly formed cells originated from duct 
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cells induced to express Pdx1 (Criscimanna, Speicher et al. 2011). Interestingly, these authors 
reported the possibility of duct cells first dedifferentiating (since there was a loss of 
expression of ductal markers) and then redifferentiating; alternatively duct cells may directly 
transdifferentiate into the various other pancreatic cell types (Criscimanna, Speicher et al. 
2011). This concept of dedifferentiation and redifferentiation of duct cells was implicated in 
the regeneration of the pancreas following partial pancreatectomy in rats (Li, Rukstalis et al. 
2010). It appears that severe pancreatic injury induces an embryological pattern of 
development in the adult pancreas, where pancreatic cells originate from ducts and TFs such 
as Pdx1 and Ngn3 are re-expressed (Li, Rukstalis et al. 2010, Criscimanna, Speicher et al. 
2011). 
In contrast to the results discussed above, others argue against duct cells as facultative islet 
progenitor cells (Cardalda et al. 2009a, Kopinke, Murtaugh 2010 Kopp, Dubois et al. 2011a, 
Solar). Lineage tracing experiments indicate that during embryological development both the 
endocrine and exocrine tissues of the pancreas arise from duct-like precursors (Solar, 
Cardalda et al. 2009b, Kopinke, Murtaugh 2010, Kopp, Dubois et al. 2011b). However, 
during normal physiological growth and following PDL, duct cells were not found to 
contribute to beta cell formation (Solar, Cardalda et al. 2009b, Kopinke, Murtaugh 2010, 
Kopp, Dubois et al. 2011b). These contradicting reports may be a result of the use of different 
models of pancreatic injury, which possibly indicates that duct cells only act as progenitor 
cells in cases of severe damage to the endocrine and exocrine compartments of the pancreas 
(Criscimanna, Speicher et al. 2011). Alternatively, the contradiction may be due to the use of 
different species and strains (Solar, Cardalda et al. 2009a). 
Furthermore, it is suggested that endocrine progenitor activity may be limited to a certain 
subgroup of ductal cells, the centroacinar or terminal duct cells (Tchokonte-Nana 2011). In 
vitro, centroacinar cells form pancreatospheres that express insulin, C-peptide or amylase 
(Rovira, Scott et al. 2010). Expression of the pro-endocrine TF Ngn3 was found to precede 
insulin expression, indicating that the centroacinar cells have endocrine progenitor activity 
(Rovira, Scott et al. 2010). In agreement with these findings, in vivo experiments where rat 
pancreatic islets were damaged by STZ report that the centroacinar cells respond by 
proliferating and subsequently start expressing insulin (Nagasao, Yoshioka et al. 2003). 
Similar to centroacinar cells, pancreatic acinar cells isolated from rats aggregate to form 
spheres in culture; acinar cells in these spheres shift towards an endocrine fate by 
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upregulating the expression of insulin, glucagon and important endocrine TFs (Song, Ko et al. 
2004). Since there was no co-expression of insulin and amylase, the authors propose that the 
acinar cells may first convert to duct-like cells before transdifferentiating to beta cells (Song, 
Ko et al. 2004). Baeyens et al. (2009) reported that Notch signalling must be overcome to 
allow Ngn3 expression before acinar cells can be converted to beta cells. Additionally, these 
authors revealed that the newly formed beta cells are immature; however, when transplanted 
into diabetic animals, the beta cells matured and were capable of regulating glycaemia 
(Baeyens, Bonne et al. 2009). In vivo, acinar cells have been converted to functional beta cells 
by the transient administration of epidermal growth factor and ciliary neurotrophic factor (two 
cytokines), and Ngn3 expression was a prerequisite for beta cell regeneration (Baeyens, 
Lemper et al. 2014).  
As previously discussed, induced expression of Pdx1, Ngn3 and MafA in a ductal cell line 
could convert duct cells to beta cells (Miyashita, Miyatsuka et al. 2014); however, in normal 
and STZ-induced diabetic mice expression of these three TFs resulted in the conversion of 
acinar cells to beta cells (Zhou, Brown et al. 2008). Moreover, different combinations of these 
TFs result in the conversion of acinar cells to other endocrine cell types (Li, Nakanishi et al. 
2014). For example, ectopic Ngn3 expression alone converted acinar cells to delta cells, while 
Ngn3 in combination with MafA converted acinar cells to alpha cells (Li, Nakanishi et al. 
2014). While these studies point out acinar cells as a source of endocrine cells, in vivo models 
of pancreatic injury (partial pancreatectomy and PDL) indicate that acinar cells only 
contributed to acinar regeneration and not to islet regeneration (Desai, Oliver-Krasinski et al. 
2007).  
The literature reviewed above gives examples of beta cell formation by means of regeneration 
from previously differentiated cellular sources; in vitro beta cells may, however, also be 
formed by means of neogenesis from mesenchymal stem cells (MSCs). Growth factors and 
hormones, obtained from pancreatic extracts of pancreatectomized rats, stimulate rat bone 
morrow-derived MSCs (BM-MSCs) to form islet like structures with beta cells in culture 
(Choi, Shin et al. 2005). Likewise, human BM-MSCs and adipose tissue-derived MSCs have 
been converted to insulin producing cells by manipulating TF expression and the culture 
microenvironment (Moriscot, de Fraipont et al. 2005, Timper, Seboek et al. 2006).  
In vivo studies have suggested that MSCs may interact with pre-existing beta cells to induce 
new beta cell formation (Tchokonte-Nana 2011). Sordi et al. (2005) found that human BM-
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MSCs express chemokines and chemokine receptors that allow their migration to the islets of 
Langerhans, a process that was confirmed to occur when these cells were transplanted into a 
mouse model. Following transplantation, BM-MSCs are located within and around islets 
(Sordi, Malosio et al. 2005, Gao, Song et al. 2014).  Gao et al. (2014) subsequently proved 
that BM-MSCs influence beta cell formation in a paracrine manner, as diabetic mice treated 
with BM-MSC conditioned medium obtained even lower blood glucose levels than diabetic 
mice treated with BM-MSC transplantation. 
While various studies discussed in this section propose different cellular sources from which 
beta cells may be generated, it is generally agreed upon that the adult pancreas does possess 
some degree of plasticity. Furthermore, it becomes apparent that the mechanism of beta cell 
formation and the source from which newly formed beta cells arise may vary depending on 
the stimulus. One possible stimulus for beta cell formation is PDL, a procedure still much 
debated in the literature. 
2.2.2.2 Pancreatic duct ligation (PDL) 
During the surgical procedure of PDL the main pancreatic duct is occluded, modelling 
pancreatic injury and reportedly inducing beta cell formation (Edstrom, Falkmer 1968, Page 
2000, Tchokonte-Nana 2011, Van de Casteele, Leuckx et al. 2013). PDL has been described 
as a good model for human pancreatitis (Meyerholz, Samuel 2007). It is important to note that 
these authors ligated the pancreatic duct close to its entrance into the duodenum, effectively 
occluding the entire duct, and causing damage to the entire pancreas (complete PDL) 
(Meyerholz, Samuel 2007). However, in models investigating beta cell formation, partial PDL 
is commonly used, in this instance the duct may be occluded at a point one third proximal to 
the tail of the pancreas, leaving a proximal segment of unligated pancreatic tissue (Tchokonte-
Nana 2011, Cavelti-Weder, Shtessel et al. 2013). Partial PDL will be further discussed and 
was used in the current study. 
Within five days following partial PDL, drastic morphological changes occur in the part of the 
pancreas distal to the ligature; these changes have been grouped into four landmarks of 
morphological similarity (Tchokonte-Nana 2011). Within one day of PDL (first landmark) 
oedema and ductal dilation can be observed, accompanied by macrophage infiltration and the 
start of acinar cell deletion (Hamamoto, Ashizawa et al. 2002, Tchokonte-Nana 2011). 
Tchokonte-Nana (2011) further reported mesenchymal proliferation during this period. Acinar 
cell death and ductal dilation continued during the second landmark (36-60 hours post-PDL) 
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(Hamamoto, Ashizawa et al. 2002, Tchokonte-Nana 2011). The third landmark (three days 
post-PDL) is characterized by complete acinar cell deletion. Acinar tissue was found to be 
remodelled by the fourth landmark (84-120 hours) (Tchokonte-Nana 2011). The four 
landmarks described above are based on a PDL model in Sprague-Dawley rats (Tchokonte-
Nana 2011) and the PDL induced morphological changes previously observed in a Wistar rat 
model correlates with these landmarks (Hamamoto, Ashizawa et al. 2002). 
In terms of morphology, the islets of Langerhans are seemingly unaffected by the surrounding 
damage to the exocrine pancreas (Tchokonte-Nana 2011). However, Catala et al. (2001) 
reported disruption of islet architecture following complete PDL in a rabbit model. In their 
model fibrotic tissue caused islets to dissociate, concomitantly inducing beta cell death 
(Catala, Daumas et al. 2001). These contradictory results may be due to the respective use of 
partial and complete PDL or the use of different species.  
In mice, PDL-induced acinar cell death is reported to occur up to 1 week post-PDL (Hakonen, 
Ustinov et al. 2011). An early PDL study did not report any acinar regeneration (Edstrom, 
Falkmer 1968), although this observation has been reported in more recent studies 
(Tchokonte-Nana 2011, Cavelti-Weder, Shtessel et al. 2013). In another study on Sprague-
Dawley rats, acinar formation was only observed 10 days post-PDL and only in one third of 
the animals studied (Page 2000). Regardless of the time frame, it is consistently reported, in 
different species and strains, that PDL induces initial apoptosis of acinar cells and 
proliferation of ductal cells (Page 2000, Hamamoto, Ashizawa et al. 2002, Xu, D'Hoker et al. 
2008, Hakonen, Ustinov et al. 2011, Chintinne, Stange et al. 2012, Rankin, Wilbur et al. 
2013). Furthermore, these morphological changes only occur in the part of the pancreas distal 
to the ligature, while the part preceding the ligature remains unaffected (Ustinov et al. 2011, 
Cavelti-Weder, Shtessel et al. 2013, Hakonen, Rankin, Wilbur et al. 2013, Hao, Lee et al. 
2013).  
In mice, beta cell volume, beta cell mass, absolute beta cell number and total islet number are 
increased in the PDL tail (part of the pancreas distal to the ligature) (D'Hoker et al. 2008, 
Hakonen, Ustinov et al. 2011, Xu, Van de Casteele, Leuckx et al. 2013). Beta cell formation 
was predominantly the result of increased replication of pre-existing beta cells; additionally, 
beta cell formation from Ngn3 positive progenitors was observed (Van de Casteele, Leuckx et 
al. 2013). Moreover, these authors report that Ngn3 expression is essential for beta cell 
formation following PDL (including for beta cell replication) (Xu, D'Hoker et al. 2008, Van 
Stellenbosch University  https://scholar.sun.ac.za
24 
  
de Casteele, Leuckx et al. 2013). In Ngn3 deficient mice, beta cell formation was decreased 
by 66% and the authors proposed that Ngn3 positive progenitors may be the source of 
replicating beta cells (Xu, D'Hoker et al. 2008). While epidermal growth factor signalling is 
essential for increased beta cell formation during pregnancy and obesity, PDL induced 
regeneration was found to occur effectively without epidermal growth factor signalling 
(Hakonen, Ustinov et al. 2011). 
When interpreting the results of PDL studies, it is important to consider the method by which 
beta cell formation was assessed. The beta cell mass is often quantified as the insulin positive 
area per area of pancreas (Hakonen, Ustinov et al. 2011, Hao, Lee et al. 2013). These results 
may overestimate beta cell formation since acinar deletion causes total pancreatic area to 
decrease and islet density to increase (Chintinne, Stange et al. 2012). Chintinne et al. (2012) 
proposes that beta cell count may provide more accurate results. These authors do not report 
an increase in total beta cell number two weeks following PDL; however, PDL resulted in an 
increase in the number of small beta cell clusters which is indicative of neogenesis (Chintinne, 
Stange et al. 2012). The formation of insulin rich endocrine areas following PDL is also 
reported in rats; these endocrine formations became indistinguishable from pre-existing islets 
by day 10 post-PDL (Page 2000). Furthermore, beta cells within these small clusters are 
reported to have increased proliferative capacity and it was hypothesised that total beta cell 
number may increase at later time points post-PDL (Chintinne, Stange et al. 2012).  
Apart from the fact that PDL has an effect on beta cells, it may also influence the other 
endocrine cell types and whole islet architecture. An increase in alpha cell number two weeks 
post-PDL has previously been reported in mice (Chintinne, Stange et al. 2012). In rats, alpha 
cells are reportedly deleted from the mantle zone of islets, while PP and delta cells appear 
within the islet core two and a half days post-PDL (Page 2000). PDL induced endocrine 
formations had a beta cell core surrounded by a thin alpha cell layer with no delta or PP cells 
(Page 2000).  
Despite mounting evidence for PDL as an effective method for inducing beta cell formation, 
recent studies present evidence to the contrary, reporting that beta cells are not generated 
following PDL (Rankin, Wilbur et al. 2013). Rankin et al. (2013) obtained similar changes in 
the exocrine pancreas as previously reported, however, in their model PDL failed to increase 
beta cell mass, beta cell proliferation or to induce conversion of non-beta cells to beta cells.  
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The PDL procedure has also been applied in combination with beta cell ablation and again 
results are contradicting. In a study where beta cells were ablated using STZ, PDL could not 
trigger beta cell formation even after 10 months (Cavelti-Weder, Shtessel et al. 2013). These 
findings are challenged by the results of a study using alloxan to destroy pre-existing beta 
cells. In this study PDL resulted in the conversion of alpha cells to beta cells (Chung, Hao et 
al. 2010). Newly formed islets in this model were disorganized and beta cell area, as well as 
blood glucose levels, did not normalize; therefore, in an attempt to rectify these abnormalities, 
the model was further elaborated by reversing the ligation one week after alloxan and PDL 
treatment (Hao, Lee et al. 2013).  Reversal of the ligature resulted in a wave of beta cell 
replication (with no additional neogenesis) that normalized beta cell area and blood glucose 
levels (Hao, Lee et al. 2013).  
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3. PROBLEM STATEMENT 
Diabetes mellitus is a metabolic disease characterized by the loss of beta cells from the islets 
(Atkinson 2000, Sherwood 2010, Kilimnik, Zhao et al. 2011), thereby disrupting islet 
composition and architecture which are important components that influence islet function 
(Weir, Samols et al. 1979, Meda, Kohen et al. 1982, Cabrera, Berman et al. 2006, Wang, 
Zhang et al. 2011, Farhat, Almelkar et al. 2013). Islet replacement therapy remains the hope 
in the treatment for diabetes, but the lack of donor organs is a clinical challenge. Novel 
techniques for the in vivo regeneration of beta cells within the adult pancreas may, however, 
be a better alternative. The use of PDL as a trigger for beta cell regeneration in the adult 
pancreas has previously been established (Wang, Kloppel et al. 1995, Page, du Toit et al. 
2000, Tchokonte-Nana 2011, Hakonen, Ustinov et al. 2011, Van de Casteele, Leuckx et al. 
2013) and the possibility that this model may have the capacity to restore normal 
islet composition and architecture could make it an effective approach to reverse diabetes. 
Many studies have attempted to study islet composition and architecture following PDL in 
diabetic animal models, but have focussed on only one or two cell types (Chung, Hao et al. 
2010). The present study is the first that has made a comprehensive investigation of islet 
composition and architecture, including the four islet cell types, and compared the effects of 
PDL treatment on both portions of the pancreas, proximal and distal to the ligature, in a 
diabetic PDL model. We hypothesise that PDL may restore islet composition and architecture 
in diabetic animals.  
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4. AIM AND OBJECTIVES 
4.1 AIM 
This study aims to determine the relative cellular composition and architecture of islets in 
STZ-induced diabetic rats and to establish the effect of PDL treatment on this composition 
and architecture.  
4.2 OBJECTIVES 
In order to achieve this aim, the following objectives were set: 
1. To assess the histomorphology of the pancreas of 
a. normal control animals 
b. STZ-induced diabetic control animals at day 0, 3, 5, 10 and 30 
c. experimental PDL treated STZ-induced diabetic animals at day 3, 5, 10 and 30; 
2. To determine islet cell type composition using protein expression of insulin, glucagon, 
somatostatin and pancreatic polypeptide in the pancreas of 
a. normal control animals 
b. STZ-induced diabetic control animals at day 0, 3, 5, 10 and 30 
c. experimental PDL treated STZ-induced diabetic animals at day 3, 5, 10 and 30; 
3. To establish the architecture of islets by identifying the distribution and location of the 
islet cell types within the islets using protein expression of insulin, glucagon, 
somatostatin and pancreatic polypeptide in the pancreas of 
a. normal control animals 
b. STZ-induced diabetic control animals at day 0, 3, 5, 10 and 30 
c. experimental PDL treated STZ-induced diabetic animals at day 3, 5, 10 and 30; 
4. To measure blood glucose and insulin levels of normal control, diabetic control and 
experimental animals  
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5. MATERIALS AND METHODS 
5.1 ETHICAL APPROVAL 
Ethical clearance was obtained from the Stellenbosch University’s Research Ethics 
Committee (ethics number SU-ACUM14-00018). The study protocol complies with the guiding 
principles laid down by Animal Welfare Organization as well as the Society for the Prevention of 
Cruelty to Animals (SPCA) and is in agreement with the ethical guidelines as proposed by the 
South African National Standard (SANS) on the care and use of animals for scientific purposes.  
5.2 THE ANIMALS 
Healthy male Wistar rats (n=55) weighing between 180-260g were randomly selected from 
the Central Animal Unit (CAU) of the Faculty of Medicine and  Health Sciences (FMHS) of  
Stellenbosch University. The rats were housed at the Animal Unit at room temperature on a 
12 hour light/dark cycle, and were fed standard rat pellets (Appendix A) with free access to 
water. Rats were weighed using an electric scale and their non-fasting blood glucose levels 
(BGL) were recorded (Appendix B) as baseline measurements. Rats were then fasted 
overnight (with water available ad libitum) prior to the induction of diabetes.  
5.2.1 Diabetes induction 
Following the fast, animals received an intraperitoneal injection of 45mg/kg streptozotocin 
(STZ) dissolved in a cold sodium citrate buffer (Appendix C). Subsequently, non-fasting BGL 
and body weight (BW) of the animals were measured every second morning (between 08:00 
and 10:00), for ten days. Animals were not fasted to avoid further stress and excessive weight 
loss. Diabetes induction was accompanied by an increase in water intake and urination. For 
this reason there was a need to add an additional bottle of water to each cage on day nine post-
STZ injection.  On day 10 post-STZ injection, animals with BGL exceeding 14.0mmol/L 
were considered diabetic and were included in the study groups. Day 10 post-STZ injection 
was considered as experimental day 0.  
5.2.2 Study groups  
Animals were divided into control animals and experimental animals (Appendix D). The 
control animals were divided into two (2) groups, the normal control (NC) group (n=6) and 
the diabetic control (DC) group (n=27). The NC group consisted of non-diabetic untreated 
rats having BGLs of less than 9.10 mmol/L and euthanized prior to the overnight fast and STZ 
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injection. The DC group consisted of diabetic rats (n=27) that did not receive further surgical 
procedure. The DC group was further divided into subgroups of 0-, 3-, 5-, 10- and 30 days 
corresponding to the day at which they were euthanized, and were named the DC0 group, 
DC3 group, DC5 group, DC10 group and DC30 group, respectively.  
The experimental animals (n=22) formed the experimental (EX) group and consisted of 
diabetic animals that received surgical procedure with a pancreatic duct ligation (PDL). The 
EX group was divided into subgroups of 3-, 5-, 10- and 30 days corresponding to the day at 
which they were euthanized, and were named the EX3 group, EX5 group, EX10 group and 
EX30 group, respectively. 
Non-fasting BGL and the BW of all animals were measured at the time points corresponding 
to the study groups. 
5.3 PANCREATIC DUCT LIGATION 
Animals in the experimental groups underwent PDL. The surgery was carried out in a surgical 
theatre of the CAU of the FMHS of Stellenbosch University. Prior to surgery, animals were 
housed in clean cages at the CAU and water and food were made available ad libitum. On the 
day of PDL, the animals were anaesthetised via the inhalation of Isofor (Appendix E) 
vaporized in oxygen. When foot or tail pinching no longer elicited a withdrawal response and 
rats had no spontaneous movement, abdominal hair (approximately 1cm) on both sides of the 
linea alba was removed with an electric shaver and the exposed skin was cleaned with 
alcohol.  
The animals were subsequently placed in dorsal recumbence on the surgical table and an 
incision was made along the midline through the linea alba, starting approximately 1cm 
inferior to the xiphoid process and extending for approximately 1.5 cm towards the pubic 
symphysis. The duodenum, stomach and spleen were identified by placing pressure on the 
lateral side of the left upper quadrant of the abdomen. The stomach and duodenum were 
drawn out and reflected cranially to expose the pancreas lying posterior to it. The pancreas 
appeared as a diffuse tissue mass and sterile cotton buds were used to carefully expose the 
pancreatic duct, which appeared as a thin translucent structure within the diffuse tissue mass 
of the pancreas. An operating microscope (Appendix E) was used to ensure correct 
identification of the pancreatic duct. A single tight suture was made with non-resorbable 
suture material to occlude the pancreatic duct at a point 1/3 proximal to the tail (splenic part) 
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of the pancreas (Figure 5.1).  Warm saline solution was introduced into the abdomen to 
prevent dehydration of the organs and the abdominal cavity was closed by two layers of 
stitching: first the muscle layer, followed by the skin layer. The PDL procedure lasted for 
about ten minutes. An antiseptic rub was applied to the wound to prevent infection and 
scratching. Intraperitoneal injections of 100 µl of Baytril, an antibiotic for the prevention of 
infection, and 100 µl Temgesic, for pain relief, were given to the animals post-operation. The 
animals were returned to their cages in a thermally controlled environment for recovery and 
were housed with free access to food and water until they were euthanized.  
To minimize the number of animal used in the study (as per the ethics requirements), no 
animals were sham operated. This exclusion follows observations made from research studies 
in the Islet Research Group at Stellenbosch University ( Page, du Toit et al. 2000, du Toit, 
Longo-Mbenza et al. 2011, Tchokonte-Nana 2011) and by many other authors (Hamamoto, 
Ashizawa et al. 2002, Chintinne, Stange et al. 2012, Rankin, Van de Casteele, Leuckx et al. 
2013, Cavelti-Weder, Shtessel et al. 2013, Wilbur et al. 2013), that there is no difference 
between sham operated and control animals and that the sham operation does not induce 
changes in the pancreas as is observed following PDL. 
 
Figure 5.1. The pancreas of the rat in-situ. Adapted image (Page 2000). 
 
 
P1 P2 
Duodenum 
Spleen 
Site of ligation 
(1/3 proximal to the tail 
of the pancreas) 
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5.4 TISSUE AND BLOOD SAMPLE COLLECTION 
5.4.1 Tissue collection 
Pancreata were collected for histological evaluation at the time points corresponding to the 
animal’s designated study group. Animals were prepared for surgery and the abdominal cavity 
was opened according to the procedures described in Section 5.3. The pancreas was exposed 
by drawing out the duodenum and stomach, and was removed along with the spleen. 
All pancreata were divided into two portions at a point 1/3 proximal to the tail of the pancreas 
(Figure 5.1). Proximal portions of the pancreata were designated as P1 tissue portions, while 
the distal portions of the pancreata were designated as P2 tissue portions. Tissue portions were 
individually placed in formalin for 48 hours prior to processing.  
5.4.2 Blood collection 
Blood samples (5 ml) were collected from the animals by cardiac puncture while they were 
under terminal anaesthesia. The samples were kept in anti-coagulation blood collection tubes 
with gel for serum separation. Animals were then euthanized by exsanguination and the 
carcases incinerated. Within two hours of collection, blood samples were centrifuged at 1000 
rmp for 10 minutes; blood serum (2 ml) was collected from each tube and stored at -80 ˚C 
until the serum insulin levels were determined using an insulin ELISA kit (Appendix F).  
5.5 HISTOLOGICAL STUDY 
5.5.1 Processing and Sectioning 
The fixed pancreatic portions were transferred to labelled cassettes and exposed to standard 
histological tissue processing procedures (Appendix G). The resulting processed tissues were 
embedded using a mould filled with melted paraffin wax (60 ˚C). Tissue blocks obtained were 
placed in a freezer to cool for approximately two hours before sectioning.  
Tissue sections were cut at 3µm thickness using a Leica RM 2125 RT microtome (Appendix 
H). Five sections were made per tissue block in the following manner: sections 1, 2 and 3 
were cut, then the tissue blocks were trimmed for a least 24 μm to ensure that different islets 
would be obtained before cutting sections 4 and 5. The first section was placed on a labelled 
frosted slide (a) and was used for the H&E staining (Figure 5.2). Sections 2 and 4 were 
mounted together on a labelled positively charged slide (b), while sections 3 and 5 were 
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mounted together on a labelled positively charged slide (c); slides b and c were used for 
immunohistochemical (IHC) staining (Figure 5.2).  
 
 
Figure 5.2. Tissue sections on a frosted slide (a) and positively charged slides (b & c). 
The tissue slides were labelled as follows: the animals’ subgroups were used as prefixes, 
individual animals were represented by the radicals A to F, the tissue portions were indicated 
by the suffixes P1 and P2, and lastly “a”, “b”, and “c” representing the sections were used as 
indices. For example, a slide labelled as DC30AP1b would indicate a slide with the 2
nd
 and 4
th
 
section made from a P1 portion of pancreas harvested from animal A in the DC30 subgroup. 
5.5.2 Haematoxylin and eosin (H&E) staining 
Haematoxylin and eosin staining was performed on all slides with index “a”, using a Leica 
Auto Stainer XL (Appendix H) with a pre-programmed protocol (Appendix I). These slides 
were used to evaluate the general morphological appearance of the pancreas of the P1 and P2 
portions of the pancreas of the different study groups. 
5.5.3 Immunohistochemical staining 
A sequential double-staining approach was used to stain pancreatic tissue sections on all 
slides with indices “b” and “c”, using a Leica Bond Max imuno-autostainer (Appendix H) 
with a pre-programmed protocol (Appendix J). All slides with index “b” were stained for 
insulin and pancreatic polypeptide using anti-insulin (MU029-UC, BIOCOMbiotech, 
Centurion, South Africa) and anti-pancreatic polypeptide (AB113694, BIOCOMbiotech, 
Centurion, South Africa) antibodies, respectively. All slides with index “c” were stained for 
glucagon and somatostatin using anti-glucagon (AB10988, BIOCOMbiotech, Centurion, 
South Africa) and anti-somatostatin (AB22682, BIOCOMbiotech, Centurion, South Africa) 
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antibodies, respectively (Appendix K). Tissues slides from NC groups were used as positive 
controls for the immunohistochemical stains. The Bond Polymer Refine Detection Kit 
(Appendix H) stained the target proteins BROWN for the antibody that was applied first 
(Insulin or glucagon), while the antibody that was applied second (pancreatic polypeptides or 
somatostatin) had the target proteins stained RED with the Bond Polymer Refine Red 
Detection Kit (Appendix H). All tissue slides were taken for manual rehydration (Appendix J) 
following the staining procedures; the slides were then mounted in DPX and cover slipped for 
viewing under the light microscope.  
5.6 MORPHOMETRIC ANALYSIS  
Immunohistochemically stained tissue sections were morphometrically analysed to determine 
islet composition and architecture. The slides were mounted under the Zeiss Aksioskop2 
microscope (serial number 801452, Carl Zeiss, AG, Oberkochen, Germany), the tissue area 
was manually scanned for islets and the image acquisition was done using AxioVision 
software (version 4.7.2.0, Carl Zeiss Microscopy, AG, Oberkochen, Germany). In each study 
group, a total number of 100 islets were used per P1 and P2 portion of the pancreas. 
Morphometric analysis of individual islets were done using the ZEN Lite 2012 software (blue 
edition, version 1.1.2.0,Carl Zeiss Microscopy GmbH, Germany) for the following 
measurements:  
1. Total islet surface area (ʎ+ʀ) [ where ʎ represents the hormone positive cells and ʀ 
represents hormone negative cells]; 
2. Islet surface area positive for insulin, glucagon, somatostatin or PP, respectively (ʎ); 
The hormone fraction (Fr) was calculated for each islet as the ratio of the surface area positive 
for a specific hormone (ʎ) to the total islet surface area (ʎ+ʀ) and was expressed as a 
percentage.  
𝐹𝑟 =
ʎ
ʎ + ʀ
 
 
The fractions from 100 islets per portion of the pancreas were used to determine the mean 
hormone fractions and this represented the islet composition in each portion of the pancreas. 
Stellenbosch University  https://scholar.sun.ac.za
34 
  
Furthermore, to consider the relative amount of each hormone present within the hormone 
positive fraction, the staining intensity of each hormone was studied and classified as none, 
low, moderate or high.  
The final islet architecture was determined using the distribution of each cell type within the 
islet and was classified as core (C-classification), mantle (M-classification) or both (B-
classification). 
5.7 STATISTICAL ANALYSIS 
Hormone fraction data were transported into STATA 13 (StataCorp, 2013, Stata: Release 13, 
Statistical Software, College Station, Texas, USA) for statistical analyses. Simple descriptive 
statistics was used to describe the variables.  No missing data was present. Data was checked 
for outliers and data errors; from the insulin fraction data one entry was excluded due to data 
entry error. Variables were tested for normality qualitatively (histograms and qq plots) and 
quantitatively. For hypothesis testing, where outcome data was not normally distributed, log 
transformations were done to obtain normality. Multilevel mixed-effects linear regression was 
used to determine differences between interventions/groups taking into account the repeated 
measurements within rats. Predictors were considered as fixed effect parameters and the 
unique rat id as the random effects.  An alpha (p-value) of 0.05 was considered statistically 
significant. No post-hoc analysis was performed. The BGL, BW, hormone staining intensity 
and cell type distribution data was used for descriptive purposes only and was not statistically 
analysed. 
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6. RESULTS 
6.1 BLOOD GLUCOSE LEVELS AND BODY WEIGHT 
6.1.1 Diabetes induction period 
The DC and EX animals (n=49) were treated with STZ to induce diabetes over a period of 10 
days. During the diabetes induction period non-fasting BGL and BW measurements were 
taken on various days, as indicated in Figure 6.1 (Appendix L and Appendix M). 
Prior to STZ injection (at baseline) these animals had an average BGL of 6.81mmol/L. 
Following the overnight fast the BGL (fasted) decreased to 4.37 mmol/L and on the same day, 
animals were injected with STZ. A sharp increase in BGL was evident as early as day one 
post-STZ injection (STZ 1d), with an average BGL of 25.68 mmol/L. By day 10 post-STZ 
injection (STZ 10d) all animals were diabetic (BGL > 14.00 mmol/L) with an average BGL of 
29.39 mmol/L.  
In addition to the BGL measurements, the effects of STZ injection were also reflected in the 
rat’s BW measurements (Figure 6.1B). Animals had an average BW of 227.2 g at baseline, 
which decreased to 216.2 g following the overnight fast. There was a fluctuation in the BW 
throughout the 10 days following STZ treatment. However, the BW still remained lower by 
day 10 (STZ 10d) than at baseline. 
STZ d10 was considered as day 0 of the experimental period and was referred to as day 0 
(d0). On this day (d0) diabetic animals were divided into a DC groups and an EX groups.  
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Figure 6.1. Column charts showing non-fasting BGL (A) and BW (B) of 49 rats for baseline, fasted 
and 10 days post-STZ injection. (STZ) streptozotocin; (d) day. 
6.1.2 Experimental period  
Non-fasting BGL and BW measurements taken during the experimental period are indicated 
in Figure 6.2 (Appendix L and Appendix M).On day 0, the BGL of all the DC and EX groups 
was >20.00 mmol/L. The EX30 group had the highest BGL (32.32 mmol/L), while the DC5 
group had the lowest BGL (24.38 mmol/L) (Figure 6.2A). On day 3, BGL was increased 
compared to day 0 in the DC3, DC5 and DC10 groups, while BGL decreased in the remaining 
DC and EX groups. On this day the DC10 groups had the highest BGL (33.30 mmol/L) and 
the DC30 group had the lowest BGL (19.46 mmol/L). On day 5, BGL increased in the EX10, 
DC30 and EX30 groups and was the highest in the EX30 group (29.04 mmol/L), while BGL 
decreased in the DC5, EX5 and DC10 groups and was the lowest in the EX5 group (23.37 
mmol/L). BGL on day 10 increased in the DC10 group to the highest value observed at this 
time point (33.30 mmol/L), while a decrease was observed in the EX10, DC30 and EX30 
group with the lowest BGL observed in the DC30 group (19.46 mmol/L). On day 30, BGL 
was increased in both the DC30 and EX30 groups. BGL was higher in the EX30 group (29.04 
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mmol/L) compared to the DC30 group (24.10 mmol/L). While the BGL fluctuated in the DC 
and EX groups over the experimental period, there was no tendency for BGL to decrease over 
time. 
Fluctuations were also observed in the animals’ BW (Figure 6.2B). On day 0, the EX5 group 
had the highest BW. By day 3, BW increase was observed in the DC3, DC5, DC30 and EX30 
groups with the DC5 group having the highest BW (227.2 g), while BW decrease was 
observed in the remaining DC and EX groups. On day 5, BW increase was observed in the 
DC5, EX5, DC10 and EX10 groups with the DC5 group having the highest BW (228.4 g); at 
the same time BW decrease was observed in the DC30 and EX30 groups. BW on day 10 was 
again decreased in the DC30 and EX30 groups, while further increase was observed in the 
DC10 and EX10 groups, with EX10 group having the highest BW (224.6 g). On day 30, BW 
increase was observed in the DC group (217.4 g), while a decrease was observed in the EX30 
group (182.6 g). Throughout the experimental period, the EX30 group recorded the lowest 
BW, ranging between 211.6 g (day 3) and 182.6 g (day 30).  
 
 
 
Figure 6.2. Line charts showing non-fasting BGL (A) and BW (B) in DC and EX groups during the 
experimental period. (DC) diabetic control; (EX) experimental. 
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6.2 SERUM INSULIN 
Serum insulin of non-fasted animals in the NC, DC and EX groups was evaluated as an 
indication of beta cell function (Appendix N). A standard curve was generated using the 
human insulin ELISA kit which is known to react with rat samples. In our samples (non-
diluted serum), few measured values were within the range of the standard curve (Figure 6.3), 
this included one animal in the NC group and 10 animals in the EX group. All other 
measurement fell below the range of the standard curve. Out of the 10 animals in the EX 
group, one measurement in the EX30 group was similar to the measurement from the NC 
group that was within the range of the standard curve. No animals in the DC groups had 
measurements within the range of the standard curve. This variation may indicate poor 
specificity of the human ELISA kit for our diabetic rat serum samples; and the fact that the 
animals were not fasted prior to blood collection could also have contributed to the variation.  
 
 
Figure 6.3. Graph showing non-fasting serum insulin samples within the range of the standard curve 
and standard measurements of the human insulin ELISA kit.   
6.3 HISTOMORPHOLOGICAL EVALUATION OF THE PANCREAS 
The microscopic slides from the NC, DC and EX groups were used to assess the 
morphological changes in the P1 and P2 portions of the pancreas (Figure 6.4 and Figure 6.5). 
6.3.1 Control groups 
In the NC group the exocrine compartment in both P1 and P2 tissue portions appeared 
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Standard curve 
Standard samples 
Our samples 
A
b
so
rb
an
ce
 (
o
p
ti
ca
l 
d
en
si
ty
, 
O
D
) 
Concentration (µIU/ml) 
Stellenbosch University  https://scholar.sun.ac.za
39 
  
ducts appeared normal. Islets of various shapes and sizes appeared pale in colour compared to 
acinar cells. These endocrine cells were densely packed and clearly delineated from 
surrounding exocrine tissue (Figure 6.4; NCP1 and NCP2). 
In all the DC groups the exocrine compartment appeared healthy in both the P1 and P2 tissue 
portions, while progressive morpho-pathological changes were observed in their islets. In the 
DC0P1 and P2 slides the islets presented with acellular areas and with an indistinct separation 
between the endocrine and exocrine compartment. Furthermore, islet cells presented with 
necrotic changes, including degranulation, hydropic changes and pyknotic nuclei (Figure 6.4; 
DC0P1 and DC0P2).  
In DC3P1 and P2 slides the pathological (necrotic) changes observed in the islets were similar 
to those of the DC0 group. In this group, however, the damage in the islets appeared more 
progressive with the presence of numerous acellular areas. Additionally, islets presented with 
an irregular shape with some islet cells having enlarged nuclei (Figure 6.4; DC3P1 and 
DCP2). This observation was common in the DC5P1 and P2 slides (Figure 6.4; DC5P1 and 
DCP2). The islet pathology observed in DC3 and DC5 groups persisted in DC10 and DC30 
groups, with a slight increase in cellular density within the islets of DC10P1, DC10P2, 
DC30P1 and DC30P2 slides (Figure 6.4; DC10P1, DC10P2, DC30P1 and DC30P2).  
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Figure 6.4. Representative H&E photomicrographs of P1 and P2 portions of the pancreas in NC and 
DC groups. Scale bar represents 100 µm. (NC) normal control; (DC) diabetic control; (P1) proximal 
portion of the pancreas; (P2) distal portion of the pancreas; (I) islet; (p) pyknotic nucleus; (h) hydropic 
changes; (a) acellular areas; (d) degranulation; (en) enlarged nucleus; (i) indistinct border. 
 
6.3.2 Experimental groups 
The EX animals presented with morphological changes in both the exocrine and endocrine 
compartments of the pancreas. Changes in the exocrine compartment differed between the P1 
portion (proximal to the ligature) and P2 portion (distal to the ligature) within the same 
pancreas. 
In the EX3P1 slides, exocrine tissues appeared unaffected by the PDL procedure (Figure 6.5; 
EX3P1). The exocrine compartment of the EX3P2 slides was severely affected by the PDL 
procedure, presenting with wide spread oedema, acinar deletion, ductal dilation and ductal 
proliferation. The islets in the P1 and P2 portions of the EX3 group presented with similar 
pathology as observed in the DC3 group; this includes degranulation, hydropic changes and 
pyknotic nuclei (Figure 6.5; EX3P1 and EX3P2). The deterioration of the morphology of the 
pancreas in the P2 portion does not allow clear delineation of islets in this portion.  
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The morphology of the exocrine tissue in the P1 portion of the EX5 group was not affected by 
the PDL procedure (Figure 6.5; EX5P1). The P2 portion presented with remodelling of the 
exocrine compartment showing healthy exocrine tissue; although some areas had oedema and 
mesenchymal proliferation (Figure 6.5; EX5P2). There was no change in the islet morphology 
in both P1 and P2 portions of the EX5 group compared to the EX3 group and islet 
morphology was similar to that observed in the DC5 group. (Hamamoto, Ashizawa et al. 
2002) 
The morphology of the exocrine tissue in the P1 and P2 portion of the EX10 group appeared 
healthy, with slight oedema and mesenchymal proliferation in the P2 portion (Figure 6.5; 
EX10P1 and EX10P2). Degenerative islets were similar in both portions (P1 and P2) of the 
EX10 group with the same morpho-pathology as observed in the DC10 group; with an 
increased cellular density within the islets of the P2 portion (Figure 6.5; EX10P2). 
The exocrine tissue in the P1 and P2 portions of the EX30 group presented with a healthy 
morphology (Figure 6.5; EX30P1 and EX30P2). The damage in the islets of this group 
appeared less pronounced in the P1 and P2 portions than in any other treated group, although 
the shape of the islets remain irregular. There was an increase in the cellular density with 
normal appearance of the nuclei. Some islet cells did, however, present with degranulation 
and hydropic changes. 
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Figure 6.5. Representative H&E photomicrographs of P1 and P2 portions of the pancreas in EX 
group. Scale bar represents 100 µm. (EX) Experimental; (P1) proximal portion of the pancreas; (P2) 
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distal portion of the pancreas(I) islet; (p) pyknotic nucleus; (h) hydropic changes; (a) acellular areas; 
(d) degranulation; (en) enlarged nucleus; (i) indistinct border (**) insert showing changes in the 
exocrine compartment. 
6.4 IMMUNOHISTOCHEMICAL EVALUATION OF ISLET COMPOSITION AND 
ARCHITECTURE IN THE PANCREAS 
6.4.1 Insulin and Pancreatic Polypeptide protein expression 
An IHC study was done to assess the protein expression of insulin and pancreatic polypeptide 
in the pancreas. The figures that follow demonstrate representative islets from the NC group 
(Figure 6.6), DC groups (Figure 6.7) and EX Groups (Figure 6.8) stained for insulin (red) and 
pancreatic polypeptide (brown). The IHC slides were used for the sole purpose of determining 
hormone fractions and to describe hormone staining intensity and distribution within the islet 
of the P1 and P2 tissue portions in the NC, DC and EX groups. 
 
 
 
Figure 6.6. Representative IHC photomicrographs of islets in the P1 and P2 portions of the NC group 
with insulin (red) and pancreatic polypeptide (brown). Scale bar represents 50 µm. (NC) normal 
control; (P1) proximal portion of the pancreas; (P2) distal portion of the pancreas. 
NCP1 NCP2 
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Figure 6.7. Representative IHC photomicrographs of islets in the P1 and P2 portions of the DC groups 
with insulin (red) and pancreatic polypeptide (brown). Scale bar represents 50µm. (DC) diabetic 
control; (P1) proximal portion of the pancreas; (P2) distal portion of the pancreas. 
 
 
 
Figure 6.8. Representative immunohistochemical photomicrographs of islets in the P1 and P2 portions 
of the EX groups with insulin (red) and pancreatic polypeptide (brown). Scale bar represents 50µm. 
(DC) diabetic control; (P1) proximal portion of the pancreas; (P2) distal portion of the pancreas. 
6.4.1.1 Insulin Fraction 
Islet insulin fraction was morphometrically determined to establish the islet composition. This 
data was log transformed and the coefficients were interpreted as a percentage change in the 
geometric mean (GM) (Table 1).  
DC30P1 
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Insulin fractions in the P1 and P2 portions were compared within each group. In the normal 
pancreata (NC group) insulin fraction was significantly higher in the P2 portion compared to 
the P1 portion (p=0.048). On average the insulin fraction GM was 16.37% higher in the P2 
portion. A significant difference in insulin fraction between P1 and P2 tissue portions was 
also observed in the DC0 group. In this group, insulin fraction GM was 54.96% higher in the 
P2 portion compared to the P1 portion (p=0.000). Conversely, insulin fraction was 
significantly lower in the P2 portion (insulin fraction GM 72.65% lower on average) 
compared to the P1 portion in the DC3 group (p=0.000). However, P1 and P2 portions did not 
differ significantly in terms of insulin fraction in the DC5 and DC10 groups (p=0.406 and 
p=0.294, respectively). There was a significant difference in the insulin fraction in the P1 and 
P2 portion of DC30 group, with the fraction in the P2 portion being higher compared to the 
P1 portion (insulin fraction GM was increased with an average of 27.75%, p=0.035). No 
significant difference was found between insulin fractions in the P1 and P2 portions of the 
EX3 and EX10 groups, respectively (p=0.110 and p=0.522, respectively). However, insulin 
fraction was significantly higher in the EX5 P2 portion compared to the EX5 P1 portion; on 
average insulin fraction GM was 54.79% higher in the P2 portion (p=0.003). Insulin fraction 
tended to be higher in the P2 portion of the EX30 group compared to the respective P1 
portions, but this was not considered significant (p=0.055). 
Insulin fractions were compared between the P1 portion of the NC group and the P1 portions 
of all DC and EX groups; similarly insulin fractions were compared between the P2 portion of 
the NC group and the P2 portions of all DC and EX groups. Both P1 and P2 portions of the 
DC and EX groups had a significant decrease in insulin fraction compared to the NC group 
(p=0.000). On average the GM of the insulin fraction in the DC and EX groups was more than 
100% lower throughout the experimental period when compared to the NC group. Moreover, 
the greatest difference was obtained in the EX30 versus the NC group, where the GM of the 
P1 and P2 portions were on average more than 200% lower.  
To further analyse the data, insulin fractions were compared between the P1 portion of the 
DC0 group and the P1 portions of the DC3, DC5, DC10, DC30 and all EX groups. In a 
similar manner the insulin fractions of the P2 portion of the DC0 group and the P2 portions of 
the DC3, DC5, DC10, DC30 and all EX groups were also compared. Only the P1 portion in 
the EX30 group (EX30P1) has a significantly lower insulin fraction compared to the insulin 
fraction of the P1 portion of the DC0 group (p=0.001), while insulin fraction in the P1 
portions in the other groups did not differ significantly from the insulin fraction of the P1 
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portions of the DC0 group (p>0.050). In the P1 portion of the EX30 group insulin fraction 
GM was on average 109.53% lower compared to the P1 portion of the DC0 group. When 
comparing P2 portions, the P2 portions of the DC3 and DC5 pancreata had significantly lower 
insulin fractions compared to the P2 portion of the DC0 group (p=0.001 and p=0.018, 
respectively). Insulin fraction GM was on average 111.47% and 85.44% lower in the P2 
portions of the DC3 and DC5 groups when respectively compared to the P2 portion of the 
DC0 group. The insulin fraction of the  P2 portions of the DC10 and DC30 groups did not 
significantly differ from the P2 portions of the DC0 group (p=0.245 and 0.280, respectively). 
In the EX3 group, the insulin fraction of the P2 portion was significantly decreased compared 
to the insulin fraction of the P2 portion of the DC0 group (p=0.025); insulin fraction GM 
being on average 76.67% lower in the P2 portion of the EX3 group. There was no significant 
difference in insulin fraction between P2 portions of the EX5 and DC0 groups (p=0.549). P2 
portions of the EX10 and EX30 groups had significantly lower insulin fractions (GM on 
average 82.08% and 127.03% lower, respectively) compared to the P2 portion of the DC0 
group (p=0.021 and p=0.000, respectively). 
Insulin fractions of the corresponding portions (P1 or P2) were compared between DC and 
EX groups of the same experimental day. On day 3, 5 and 10 insulin fraction did not 
significantly differ between DC and EX groups when comparing both the P1 and P2 portions, 
respectively (p>0.050). On day 30 insulin fraction in the P1 portions differed significantly 
between DC and EX groups (p=0.001); the insulin fraction GM in the P1 portion of the EX30 
groups was on average 101.20% lower compared to insulin fraction of the P1 portion of the 
DC30 group. Insulin fraction did not differ significantly in the P2 portions between the DC30 
and EX30 groups (p=0.065). 
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Table 1. Insulin fraction data summary for 100 islets per portion of the pancreas 
Group  
25
th
 
percentile 
50
th
 
percentile 
(median) 
75
th
 
percentile 
Arithmetic mean 
[95%CI] 
Geometric mean 
(GM)  
[95%CI] 
NC P1 63.30 74.82 82.06 67.42 [62.79-72.54] 58.72 [51.14-67.42] 
 P2 71.61 78.24 85.82 73.91 [70.23-77.79] 68.72 [62.48-75.56] 
DC0 P1 0.68 11.62 23.12 14.90 [11.91-17.89] 13.58 [10.70-17.23] 
 P2 8.87 22.91 36.33 24.15 [20.43-27.88] 22.68 [19.31-26.65] 
DC3 P1 5.01 11.72 25.95 17.57 [14.08-21.06] 15.57 [12.94-18.73] 
 P2 1.92 5.97 12.59 9.37 [6.94-11.81] 7.57 [6.14-9.33] 
DC5 P1 2.09 7.96 18.00 17.34 [12.55-22.13] 11.49 [8.86-14.90] 
 P2 0.59 4.87 23.15 17.83 [12.79-22.86] 11.39 [8.46-15.35] 
DC10 P1 0.00 8.11 24.41 14.10 [10.74-17.45] 16.58 [13.23-20.78] 
 P2 0.00 0.00 13.81 9.85 [6.67-13.02] 14.14 [11.02-18.12] 
DC30 P1 2.73 9.24 21.75 16.81 [12.59-21.03] 13.00 [10.30-16.41] 
 P2 0.00 10.06 34.12 20.88 [16.13-25.63] 18.21 [13.96-23.74] 
EX3 P1 3.64 9.80 22.29 22.70 [7.41-37.98] 13.90 [11.17-17.30] 
 P2 3.16 9.32 21.53 14.85 [11.64-18.06] 11.36 [8.91-14.49] 
EX5 P1 0.00 0.00 11.06 7.82 [5.24-10.41] 10.34 [7.45-14.35] 
 P2 0.00 10.43 27.17 16.51 [12.74-20.27] 18.48 [15.01-22.76] 
EX10 P1 0.00 3.72 13.19 8.59 [5.97-11.21] 11.06 [8.75-13.99] 
 P2 1.27 7.61 15.52 11.00 [8.54-13.46] 10.01 [8.15-12.29] 
EX30 P1 0.00 0.00 3.53 11.66 [-5.11-28.43] 4.94 [3.44-7.10] 
 P2 0.00 1.99 7.65 6.76 [4.22-9.31] 6.54 [4.89-8.74] 
 
(NC) normal control; (DC) diabetic control; (EX) experimental; (P1) proximal portion of the pancreas; 
(P2) distal portion of the pancreas. 
6.4.1.2 Insulin Staining Intensity 
Insulin staining intensity was observed and classified as none, low, moderate or high. Figure 
6.9 represents insulin staining intensity obtained from 100 islets per tissue portion (P1 and P2) 
in each one of the study groups.  
All islets in the NC group stained positive for insulin, with predominantly high insulin 
staining intensity in the islets in the P1 and P2 portions. Insulin staining intensity in the P1 
and P2 portions of the DC0, DC3 and DC5 groups were predominantly classified as moderate 
and low. This was also the case in the P1 portion of the DC10 group. In the DC30 and EX3 
groups insulin staining intensity was predominantly classified as low and none (for both P1 
and P2 portions). This was also the case for the P2 portions of the EX5, EX10 and EX30 
groups. In DC and EX groups some islets were devoid of insulin expression; in the P1 
portions of the EX5 and EX30 groups and in the P2 portion of the DC10 group more than 
50% of the islets were devoid of insulin (staining intensity classified as “none”). 
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Figure 6.9. Chart showing the insulin staining intensity obtained from 100 islets per tissue portion (P1 
and P2) in NC, DC and EX groups. (NC) normal control; (DC) diabetic control; (EX) experimental; 
(P1) proximal portion of the pancreas; (P2) distal portion of the pancreas. 
6.4.1.3 Insulin Distribution 
Insulin positive cells in NC, DC and EX groups were classified according to their locations 
within the islet as core (C-classification), mantle (M-classification) or both (B-classification). 
The distribution of insulin positive cells in the P1 and P2 portions of the pancreas of each 
study group is represented in Figure 6.10. 
In the NC group insulin positive cells were mostly seen as a single cluster of beta cells 
extending from the core to the mantle (B-classification) of the islet predominantly. A few 
islets had insulin positive cells exclusively within the islet core (C-classification) in the P1 
portion of the NC group.  
In DC and EX groups insulin positive cells were seen in both the core and the mantle (B-
classification), but did not form a single cluster as was seen in the NC group; this reflects the 
decrease in insulin positive area. Most insulin positive islets were predominantly B-
classification in DC and EX groups, except in the P2 portion of the DC3 group and in the P1 
portion of the EX30 group, where C-classification was most frequently observed. M-
classification was observed in only one islet in the P1 portion of the NC group. However, M-
classification appeared in DC end EX groups, but was not predominant in any portions of the 
pancreas.   
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Figure 6.10. Chart showing the distribution of insulin positive cells within the islets of NC, DC and 
EX groups. (C-classification) core; (M-classification) mantle; (B-classification) both; (NC) normal 
control; (DC) diabetic control; (EX) experimental; (P1) proximal portion of the pancreas; (P2) distal 
portion of the pancreas. 
6.4.1.4 Pancreatic Polypeptide Fraction 
Islet pancreatic polypeptide fraction was morphometrically determined to establish the islet 
composition. This data was log transformed and the coefficients were interpreted as a 
percentage change in the geometric mean (GM) (Table 2).  
PP fractions in the P1 and P2 portions were compared within each group. The PP fraction did 
not significantly differ between the P1 and P2 portions of the NC group (p=0.635). In the 
DC0 group, however, PP fraction was significantly lower in the P2 portion compared to the 
P1 portion (p=0.000). The PP fraction GM was on average 88.58% lower in the P2 portion of 
the DC0 group compared to the P1 portion of the DC0 group. P1 and P2 portions did not 
significantly differ in terms of PP fraction in the DC3 group (p=0.255). PP fraction GM was 
on average 35.28% lower in the P2 portion of the DC5 group compared to the P1 portion of 
the DC5 group (p=0.006). DC10 and DC30 groups also had significantly lower PP fractions 
in their P2 portions compared to their respective P1 portions (p=0.005 and p=0.000, 
respectively). In the P2 portions of the DC10 and DC30 groups PP fraction GM was on 
average 38.05% and 74.65% lower when respectively compared to their P1 portions. The 
EX3, EX5 and EX30 groups all had significantly lower PP fractions in their P2 portions 
compared to their P1 portions (p=0.000, p=0.001 and p=0.000, respectively). In these three 
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groups PP fraction GM was on average 53.61%, 44.93% and 46.34% lower in the respective 
P2 portions compared to their P1 portions. No significant difference in PP fraction was found 
between P1 and P2 portions in the EX10 group (p=0.090).  
PP fractions were compared between the P1 portion of the NC group and the P1 portions of 
all DC and EX groups; similarly PP fractions were compared between the P2 portion of the 
NC group and the P2 portions of all DC and EX groups. All P1 and P2 portions of the DC and 
EX groups had a significant decrease in PP fraction compared to the NC group (p=0.000), 
except the P2 portion of the DC10 group which did not differ from the P2 portion of the NC 
group (p=0.963). In the P1 portions of the DC0, DC3, DC5, DC10 and DC30 groups PP 
fraction GM was 146.93%, 92.94%, 104.62%, 47.96% and 169.72% higher when respectively 
compared to the P1 portion of the NC group. PP fraction GM in the P1 portions of the EX3, 
EX5, EX10 and EX30 groups was on average 183.46%, 118.56%, 80.58% and 144.84% 
higher when respectively compared to the P1 portion of the NC group. When comparing P2 
portions, the PP fraction GM was on average 50.45%, 100.16%, 66.30% and 85.67% higher 
in the DC0, DC3, DC5 and DC30 groups, respectively, compared to the P2 portion of the NC 
group. PP fraction was also higher in the P2 portions of the EX3, EX5, EX10 and EX30 
groups compared to P2 portions of the NC group; PP fraction GM being an average of 
120.53%, 66.03%, 53.31% and 91.64% higher in these groups, respectively. 
PP fractions were compared between the P1 portion of the DC0 group and the P1 portions of 
the DC3, DC5, DC10, DC30 and all EX groups; similarly PP fractions were compared 
between the P2 portion of the DC0 group and the P2 portions of the DC3, DC5, DC10, DC30 
and all EX groups. P1 portions of the DC3, DC5 and DC10 groups had significantly lower PP 
fractions compared to the P1 portion of the DC0 group (p=0.007, p=0.034 and p=0.000); the 
PP fraction GM was on average 53.89%, 42.26% and 98.81% lower in in the P1 portions of 
these groups. PP fraction in the P1 portion of the DC30 group did not differ significantly from 
the PP fraction in the P1 portion of the DC0 group (p=0.561). The P1 portions of the EX3, 
EX5 and EX30 groups did not significantly differ from the P1 portion of the DC0 group in 
terms of PP fraction (p=0.062, p=0.147 and p=0.920, respectively). PP fraction GM was, 
however, on average 66.31% lower in the P1 portion of the EX10 group compared to the P1 
portion of the DC0 group (p=0.001). When comparing the P2 portions, the DC3 group tended 
to have a PP fraction GM that was 49.75% higher on average than the PP fraction GM in the 
P2 portion of the DC0 group; this difference was, however, not significant (p=0.052). No 
significant difference was found between the P2 portions of the DC5, DC10 and DC30 groups 
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compared to the P2 portion of the DC0 group (p=0.550, p=0.069 and p=0.190, respectively). 
The P2 portions of the EX3 group had a PP fraction GM that was on average 70.06% higher 
than that of the P2 portion of the DC0 group (p=0.006). PP fraction in the P2 portions of the 
EX5, EX10 and EX30 groups did not significantly differ from the P2 portion of the DC0 
group (p=0.548, p=0.917 and P=0.125, respectively). 
PP fractions of corresponding portions (P1 or P2) were compared between the DC and EX 
groups of the same experimental day. PP fraction GM was on average 90.82% higher in the 
P1 portion of the EX3 group compared to the P1 portion of the DC3 group (p=0.000), while 
PP fraction did not differ significantly between the P2 portions of the DC3 and EX3 groups 
(p=0.413). No significant difference was found between PP fractions of the DC5 and EX5 
groups when comparing both P1 and P2 portions (p=0.543 and p=0.976, respectively). 
Likewise, the PP fraction in the P1 portion of the EX10 group did not significantly differ from 
the PP fraction in the P1 portion of the DC10 group. In the P2 portion, however, EX10 
pancreata had a significantly higher PP fraction compared to the DC10 group (p=0.034); in 
the P2 portion of the EX10 group PP fraction GM was on average 52.22% higher. DC30 and 
EX30 groups did not differ significantly when comparing PP fractions in both the P1 and P2 
portions (p=0.142 and p=0.789, respectively). 
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Table 2. Pancreatic polypeptide fraction data summary for 100 islets per portion of the pancreas 
Group  
25
th
 
percentile 
50
th
 
percentile 
(median) 
75
th
 
percentile 
Arithmetic mean 
[95%CI] 
Geometric mean 
(GM)  
[95%CI] 
NC P1 0.79 3.97 7.24 6.01 [4.36-7.67] 4.93 [3.95-6.14] 
 P2 0.98 4.10 8.48 6.72 [5.10-8.33] 5.30 [4.24-6.63] 
DC0 P1 8.13 20.45 37.52 26.89 [22.08-31.71] 21.28 [17.51-25.85] 
 P2 2.54 7.84 15.50 11.63 [8.85-14.40] 8.67 [7.02-10.72] 
DC3 P1 0.00 7.88 19.37 12.27 [9.63-14.91] 12.12 [9.84-14.92] 
 P2 7.76 14.20 24.32 18.09 [15.02-21.15] 14.04 [11.92-16.53] 
DC5 P1 8.27 13.15 22.33 17.15 [14.23-20.07] 13.80 [11.66-16.33] 
 P2 3.67 7.97 19.24 13.00 [10.28-15.71] 9.82 [7.95-12.12] 
DC10 P1 2.31 5.84 9.72 8.61 [6.53-10.69] 7.63 [6.32-9.21] 
 P2 0.00 3.93 7.68 5.57 [4.16-6.99] 5.30 [4.36-6.43] 
DC30 P1 11.00 25.50 43.83 28.74 [24.29-33.19] 26.41 [22.14-31.50] 
 P2 4.56 9.41 21.26 14.68 [11.68-17.68] 12.65 [10.60-15.10] 
EX3 P1 11.56 30.50 56.23 33.88 [28.63-39.12] 31.01 [26.09-36.86] 
 P2 8.02 18.81 36.96 23.09 [19.68-26.50] 17.63 [14.63-21.24] 
EX5 P1 5.61 13.95 27.18 20.14 [16.25-24.03] 15.65 [12.81-19.12] 
 P2 2.95 6.53 18.96 13.54 [10.47-16.60] 10.25 [8.20-12.81] 
EX10 P1 4.97 10.18 15.70 12.52 [9.90-15.15] 10.89 [9.22-12.86] 
 P2 1.61 7.73 14.43 11.12 [8.67-13.56] 9.12 [7.33-11.35] 
EX30 P1 13.15 20.60 40.27 26.94 [22.65-31.22] 20.44 [17.16-24.35] 
 P2 4.25 12.14 22.96 16.83 [13.25-20.12] 13.53 [11.17-16.40] 
 
(NC) normal control; (DC) diabetic control; (EX) experimental; (P1) proximal portion of the pancreas; 
(P2) distal portion of the pancreas. 
6.4.1.5 Pancreatic Polypeptide Intensity 
Pancreatic polypeptide staining intensity was observed and classified as none, low, moderate 
or high. Figure 6.11 represents pancreatic polypeptide staining intensity obtained from 100 
islets per tissue portion (P1 and P2) in each one of the study groups.  
In all groups PP staining intensity was predominantly classified as high, except in the P1 
portion of the DC10 group and the P2 portions of the DC10 and EX10 groups, where PP 
staining intensity was predominantly classified as moderate. In these three groups only a 
small number of islets were classified as staining with high intensity (11, 6 and 5 islets, 
respectively). Islets devoid of PP staining were observed in all groups; however, in the P1 
portions of the DC5 and EX30 groups and in the P2 portions of the DC3 and EX3 groups less 
than 10 islets were observed to have no PP staining. 
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Figure 6.11. Chart showing pancreatic polypeptide staining intensity obtained from 100 islets per 
tissue portion (P1 and P2) in NC, DC and EX groups. (NC) normal control; (DC) diabetic control; 
(EX) experimental; (P1) proximal portion of the pancreas; (P2) distal portion of the pancreas. 
6.4.1.6 Pancreatic Polypeptide Distribution 
Pancreatic polypeptide positive cells in NC, DC and EX groups were classified according to 
their locations within the islet as core (C-classification), mantle (M-classification) or both (B-
classification). The distribution of PP positive cells in the P1 and P2 portions of the pancreas 
of each study group is represented in Figure 6.12. 
PP positive cells were predominantly located within the mantle of islets in the NC groups (M-
classification). These positively staining cells were observed as single cells, pairs of cells or 
small groups of cells (3-4 cells). Following diabetes induction, M-classification was less 
frequently observed and B-classification for PP positive cells became predominant in all DC 
and EX groups. Again these cells were present as single cells, pairs of cells or small groups; 
however, larger groups of PP cells were observed and were dispersed throughout the islet. In 
some islets it was observed that PP positive cells were taking up a large part of the islet. Over 
all there were only a few cases in the NC, DC and EX groups where PP positive cells were 
located exclusively within the core (C-classification) of the islet.  
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Figure 6.12. Chart showing distribution of pancreatic polypeptide positive cells within the islet of NC, 
DC and EX groups. (C-classification) core; (M-classification) mantle; (B-classification) both; (NC) 
normal control; (DC) diabetic control; (EX) experimental; (P1) proximal portion of the pancreas; (P2) 
distal portion of the pancreas. 
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6.4.2 Glucagon and Somatostatin protein expression 
An immunohistochemical study was done to assess the protein expression of glucagon and 
somatostatin in the pancreas. The figures that follow demonstrate representative islets from 
the NC group (Figure 6.13), DC groups (Figure 6.14) and EX Groups (Figure 6.15) stained 
for glucagon (red) and somatostatin (brown). The IHC slides were used for the sole purpose 
of determining hormone fractions and to describe hormone staining intensity and distribution 
within the islet of the P1 and P2 tissue portions in the NC, DC and EX groups. 
 
 
 
Figure 6.13. Representative immunohistochemical photomicrographs of islets in the P1 and P2 
portions of the NC group with glucagon (red) and somatostatin (brown). Scale bar represents 50 µm. 
(NC) normal control; (P1) proximal portion of the pancreas; (P2) distal portion of the pancreas. 
 
 
 
Figure 6.14. Representative immunohistochemical photomicrographs of islets in the P1 and P2 
portions of the DC groups with glucagon (red) and somatostatin (brown). Scale bar represents 50 µm. 
(DC) diabetic control; (P1) proximal portion of the pancreas; (P2) distal portion of the pancreas. 
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Figure 6.15. Representative IHC photomicrographs of islets in the P1 and P2 portions of the DC 
groups with glucagon (red) and somatostatin (brown). Scale bar represents 50 µm. (DC) diabetic 
control; (P1) proximal portion of the pancreas; (P2) distal portion of the pancreas. 
6.4.2.1 Glucagon Fraction 
Islet glucagon fraction was morphometrically determined to establish the islet composition. 
This data was normally distributed; therefore coefficients are interpreted as per normal 
regression (Table 3).  
Glucagon fractions in the P1 and P2 portions were compared within each group. Glucagon 
fraction tended to be 3.98% lower in the P2 portion compared to the P1 portion of the NC 
group (95%CI -7.98, 0.02; p=0.051). In the DC0 group there was no significant difference 
between glucagon fraction in the P1 and the P2 portions of the pancreas (p=0.675). Similarly, 
no significant difference was found between glucagon fraction in the P1 and P2 portions of 
the DC5 group. Glucagon fraction was, however, significantly higher in the P2 portions of the 
DC3 group (with 6.50%; 95%CI 1.12, 11.88; p=0.018), DC10 group (with 5.16%, 95%CI 
0.34, 9.98; p=0.036) and DC30 group (with 6.71%; 95%CI 1.15, 12.26; p=0.018) when 
compared to their respective P1 portions. Glucagon fraction did not differ significantly 
between the P1 and P2 portions of the EX3, EX5, EX10 and EX30 groups (p=0.171, p=0.529, 
p=0.855 and p=0.071, respectively). 
Glucagon fractions were compared between the P1 portion of the NC group and the P1 
portions of all DC and EX groups; similarly glucagon fractions were compared between the 
P2 portion of the NC group and the P2 portions of all DC and EX groups. All P1 portions of 
the DC and EX groups had significant higher glucagon fractions, compared to the P1 portion 
of the NC group (p=0.000). Glucagon fraction was on average more than 30% higher in in all 
EX30P2 EX30P1 EX10P1 
EX3P1 EX3P2 EX5P1 EX5P2 
EX10P2 
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P1 portions of the DC and EX groups. Similarly, all P2 portions of the DC and EX groups had 
a significantly higher glucagon fraction compared to the P2 portion of the NC group 
(p=0.000); glucagon fraction was on average more than 35% higher in all P2 portions of the 
DC and EX groups. 
Glucagon fractions were compared between the P1 portion of the DC0 group and the P1 
portions of the DC3, DC5, DC10, DC30 and all EX groups; similarly glucagon fractions were 
compared between the P2 portion of the DC0 groups and the P2 portions of the DC3, DC5, 
DC10, DC30 and all EX groups. Glucagon fractions did not significantly differ between the 
DC0 group and the DC3, DC5, DC10, DC30 and all EX groups when comparing the P1 
portions (p=0.5375) and the P2 portions (p=0.4391). 
Glucagon fractions of corresponding portions (P1 or P2) were compared between DC and EX 
groups of the same experimental day. Glucagon fractions in both the P1 and P2 portions did 
not differ when comparing the DC and EX groups of day 3, 5 and 30 (p>0.1). Similarly, the 
P1 portions of the DC10 group and EX10 group did not differ significantly in terms of 
glucagon fraction (p=0.591). The P2 portions of the DC10 group and EX10 group did, 
however, have significantly different glucagon fractions (p=0.036); glucagon fraction was 
4.74% (95%CI -9.16, -0.31) lower in the P2 portion of the EX10 group compared to the P2 
portion of the DC10 group. 
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Table 3. Glucagon fraction data summary for 100 islets per portion of the pancreas 
Group  
25
th
 
percentile 
50
th
 
percentile 
(median) 
75
th
 
percentile 
Arithmetic mean 
[95%CI] 
Geometric mean 
(GM)  
[95%CI] 
NC P1 18.02 24.45 35.25 27.61 [24.92-30.29] 25.26 [22.93-27.82] 
 P2 15.28 21.46 28.51 23.83 [20.78-26.89] 21.05 [18.62-23.79] 
DC0 P1 53.52 63.76 75.23 63.04 [59.37-66.71] 59.23 [54.72-64.12] 
 P2 55.28 65.77 78.94 64.13 [60.50-67.76] 60.54 [56.14-65.29] 
DC3 P1 44.26 57.34 71.70 57.56 [53.80-61.32] 53.85 [49.80-58.24] 
 P2 49.74 66.28 80.20 64.06 [59.54-68.59] 57.88 [52.08-64.34] 
DC5 P1 48.75 63.74 74.78 60.46 [56.46-64.45] 55.70 [50.83-61.04] 
 P2 48.83 62.14 75.10 59.37 [55.27-63.46] 55.31 [50.40-60.70] 
DC10 P1 58.67 71.68 80.46 67.68 [63.64-71.72] 61.92 [55.45-69.15] 
 P2 63.24 74.80 82.04 72.84 [70.03-75.64] 71.35 [68.42-74.40] 
DC30 P1 44.26 64.55 78.23 58.14 [53.03-63.25] 52.98 [46.68-60.12] 
 P2 52.81 69.22 82.60 65.59 [61.41-69.77] 60.06 [54.10-66.69] 
EX3 P1 55.02 70.55 84.02 66.10 [62.07-70.14] 61.67 [56.66-67.12] 
 P2 61.42 72.01 80.98 69.26 [65.70-72.82] 64.62 [58.21-71.73] 
EX5 P1 52.48 65.30 76.65 61.48 [57.57-65.40] 58.47 [53.17-64.29] 
 P2 53.82 63.58 75.39 62.97 [59.63-66.30] 60.18 [56.38-64.24] 
EX10 P1 60.29 70.40 80.61 67.43 [63.70-71.16] 61.45 [54.55-69.21] 
 P2 55.04 71.12 79.71 66.97 [63.40-70.55] 63.12 [58.14-68.52] 
EX30 P1 50.32 65.14 80.73 64.47 [60.32-68.61] 57.18 [48.94-66.82] 
 P2 58.33 70.35 81.55 69.14 [66.05-72.23] 66.91 [63.27-70.76] 
 
(NC) normal control; (DC) diabetic control; (EX) experimental; (P1) proximal portion of the pancreas; 
(P2) distal portion of the pancreas. 
6.4.2.2 Glucagon Staining Intensity 
Glucagon staining intensity was observed and classified as none, low, moderate or high. 
Figure 6.16 represents glucagon staining intensity obtained from 100 islets per tissue portion 
(P1 and P2) in each one of the study groups.  
Glucagon staining intensity was predominantly classified as high in all groups. In the normal 
group, six islets devoid of glucagon were observed, while only seven islets in total were 
devoid of glucagon in all DC and EX groups. 
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Figure 6.16. Chart showing glucagon staining intensity obtained from 100 islets per tissue portion (P1 
and P2) in NC, DC and EX groups. (NC) normal control; (DC) diabetic control; (EX) experimental; 
(P1) proximal portion of the pancreas; (P2) distal portion of the pancreas. 
6.4.2.3 Glucagon Distribution 
Glucagon positive cells in NC, DC and EX groups were classified according to their locations 
within the islet as core (C-classification), mantle (M-classification) or both (B-classification). 
The distribution of glucagon positive cells in the P1 and P2 portions of the pancreas of each 
study group is represented in Figure 6.17. 
In the NC group, glucagon positive cells were predominantly located in the mantle of the islet 
(M-classification) where these cells formed a discontinuous layer. Glucagon distribution was 
disrupted in all treated pancreata (DC and EX groups). The discontinuous glucagon layer 
appeared expanded, extending from the mantle into the islet core, therefore B-classification 
became predominant. In some islets glucagon positive cells took up the largest area of the 
islet. Only one islet was observed where glucagon appeared exclusively in the islet core (C-
classification) (EX10P1).  
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Figure 6.17. Chart showing distribution of glucagon positive cells within the islets of NC, DC and EX 
groups. (C-classification) core; (M-classification) mantle; (B-classification) both; (NC) normal 
control; (DC) diabetic control; (EX) experimental; (P1) proximal portion of the pancreas; (P2) distal 
portion of the pancreas. 
6.4.2.4 Somatostatin Fraction 
Islet somatostatin fraction was morphometrically determined to establish the islet 
composition. This data was log transformed and the coefficients were interpreted as a 
percentage change in the geometric mean (GM) (Table 4).  
Somatostatin fractions in the P1 and P2 portions were compared within each group. The P2 
portion of the NC group had a significant higher somatostatin fraction compared to the P1 
portion of the NC group (p=0.000). On average, somatostatin fraction GM was 62.04% higher 
in the P2 portion compared to the P1 portion of the NC pancreata. Somatostatin fraction GM 
was also significantly increased (with an average of 39.97%) in the P2 portion of the DC0 
group compared to the P1 portion of the DC0 group (p=0.001). The two portions of the 
pancreas did not significantly differ in terms of somatostatin fraction in the DC3 and DC10 
groups (p=0.162 and p=0.297, respectively). Somatostatin fraction did, however, significantly 
differ between the respective P1 and P2 portions of the DC5 and DC30 groups (p=0.003 and 
p=0.000). In these two groups somatostatin fraction GM of the P2 portions was respectively 
42.08% and 60.28% lower compared to their P1 portions. No significant difference in 
somatostatin fraction was observed between the P1 and P2 portions of the EX3, EX5 and 
EX10 groups, respectively (p=0.322, p=0.843 and p=0.411, respectively). In the EX30 group, 
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however, somatostatin fraction was significantly lower in the P2 portion compared to the P1 
portion (p=0.00); in the P2 portion the somatostatin fraction GM was on average 94.02% 
lower. 
Somatostatin fractions were compared between the P1 portion of the NC group and the P1 
portions of all DC and EX groups; similarly, somatostatin fractions were compared between 
the P2 portion of the NC group and the P2 portions of all DC and EX groups. Somatostatin 
fraction was significantly increased in the P1 portions of the DC0 and DC3 groups compared 
to the P1 portion of the NC group (p=0.013 and p=0.005 respectively). On average the 
somatostatin fraction GM was 42.55% higher in the P1 portions of the DC0 group and 
47.46% higher in the P1 portion of the DC3 group when respectively compared to the P1 
portion of the NC group. No significant difference in somatostatin fraction was found when 
comparing the P1 portions of the DC5 and DC10 groups to P1 portion of the NC group 
(p=0.378 and p=0.741, respectively). The P1 portions of the EX3, EX5 and EX10 groups also 
did not significantly differ when compared to the P1 portion of the NC group (p=0.443, 
p=0.308 and p=0.631, respectively). On day 30, however, the P1 portions of both the DC30 
and EX30 groups had a significant higher somatostatin fraction compared to the P1 portion of 
the NC group (p=0.000 in both cases). In the P1 portion of the DC30 group somatostatin 
fraction GM was on average 72.16% higher compared to normal, while in EX30P1 pancreata 
somatostatin fraction GM was 129.58% higher compared to the NC group. When comparing 
P2 portions, the DC0, DC3, DC10 and DC30 groups’ somatostatin fraction did not differ 
significantly from the P2 portion of the NC group (p=0.380, p=0.175, p=0.205 and p=0.061, 
respectively). The P2 portion of the DC5 group did, however, have a significantly lower 
somatostatin fraction compared to the P2 portion of the NC group (p=0.001). The 
somatostatin fraction GM was on average 87.30% lower in the P2 portion of the DC5 group. 
Somatostatin fraction in the P2 portions of the EX5 and EX30 groups did not differ 
significantly from the somatostatin fraction in the P2 portion in the NC group (p=0.071 and 
p=0.314, respectively), while somatostatin fraction GM was significantly lower (with 90.15% 
and 62.65% on average, respectively) in the P2 portions of the EX3 and EX10 groups 
compared to the P2 portion of the NC group (p=0.001 and p=0.015, respectively). 
Somatostatin fractions were compared between the P1 portion of the DC0 group and the P1 
portions of the DC3, DC5, DC10, DC30 and all EX groups; similarly, somatostatin fractions 
were compared between the P2 portion of the DC0 group and the P2 portions of the DC3, 
DC5, DC10, DC30 and all EX groups. Somatostatin fraction did not significantly differ when 
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comparing the P1 portions of the DC3, DC5 and DC30 groups to the P1 portion of the DC0 
group (p=0.764, p=0.110 and p=0.075, respectively). A significant difference was found 
between the P1 portions of the DC10 and DC0 groups (p=0.043); somatostatin fraction GM 
was on average 36.18% lower than in the P1 portion of the DC10 group. P1 portions of the 
EX5 and EX10 groups did not significantly differ from the P1 portion of the DC0 group in 
terms of somatostatin fraction (p=0.145 and p=0.092, respectively). Somatostatin fractions of 
the P1 portions of the EX3 and EX30 groups did, however, differ significantly from the P1 
portion of the DC0 group (p=0.001 and p=0.000, respectively). The P1 portions of the EX3 
and EX30 groups had a somatostatin fraction GM that was on average 56.28% lower and 
87.04% higher, respectively, when compared to the P1 portion of the DC0 group. 
Somatostatin fraction was significantly lower in the P2 portions of the DC3, DC5, DC10, 
DC30, EX3, EX5 and EX10 groups (p<0.050) In all of these groups the somatostatin fraction 
GM was on average more than 54% lower compared to the P2 portion of the DC0 group. 
Only the P2 portion of the EX30 group did not significantly differ from the P2 portion of the 
DC0 group (p=0.063). 
Somatostatin fractions of corresponding portions (P1 or P2) were compared between DC and 
EX groups of the same experimental day. A significant difference was observed between the 
P1 portions of the DC3 and EX3 groups’ somatostatin fraction (p=0.014). The somatostatin 
fraction GM was on average 63.41% lower in the EX3 group. The P2 portions did not 
significantly differ between DC3 and EX3 groups in terms of somatostatin fraction (p=0.100). 
The somatostatin fractions in the DC5 and EX5 groups did not significantly differ when 
respectively comparing their P1 and P2 portions (p=0.918 and p=0.120, respectively). The P1 
portions of the DC10 and EX10 groups did not significantly differ in terms of somatostatin 
fractions (p=0.998); at this time point, however, P2 portions of the EX10 group had a 
significantly lower somatostatin fraction GM (31.29% on average) compared to the DC10 
group. Conversely, somatostatin fraction GM was on average 57.42% higher in the P1 portion 
of the EX30 group compared to the P1 portion of the DC30 group (p=0.001). No significant 
difference was found between somatostatin fraction in the P2 portions of the DC30 and EX30 
groups (p=0.428). 
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Table 4. Somatostatin fraction data summary for 100 islets per portion of the pancreas 
Group  
25
th
 
percentile 
50
th
 
percentile 
(median) 
75
th
 
percentile 
Arithmetic mean 
[95%CI] 
Geometric mean 
(GM)  
[95%CI] 
NC P1 0.53 1.42 3.56 2.45 [1.84-3.05] 2.15 [1.75-2.64] 
 P2 2.06 3.85 7.39 5.32 [4.32-6.31] 3.93 [3.27-4.73] 
DC0 P1 1.60 2.87 5.18 3.85 [3.21-4.49] 3.28 [2.82-3.81] 
 P2 2.52 5.13 7.89 6.40 [5.23-7.58] 4.90 [4.08-5.89] 
DC3 P1 1.71 2.88 5.91 4.96 [3.72-6.20] 3.45 [2.84-4.19] 
 P2 0.71 2.10 5.36 3.78 [2.79-4.78] 2.75 [2.19-3.46] 
DC5 P1 0.78 2.41 3.78 2.80 [2.27-3.34] 2.51 [2.11-2.99] 
 P2 0.40 1.07 2.65 2.19 [1.58-2.79] 1.63 [1.29-2.06] 
DC10 P1 0.00 1.05 2.78 2.89 [1.76-4.01] 2.36 [1.79-3.12] 
 P2 0.00 1.45 2.99 2.63 [1.86-3.41] 2.84 [2.28-3.53] 
DC30 P1 2.00 4.06 7.79 6.07 [4.71-7.41] 4.41 [3.67-5.31] 
 P2 0.34 1.83 4.09 2.93 [2.18-3.67] 2.52 [2.03-3.13] 
EX3 P1 0.00 1.02 2.57 1.89 [1.38-2.39] 1.90 [1.50-2.41] 
 P2 0.00 0.00 1.38 0.96 [0.64-1.28] 1.59 [1.21-2.10] 
EX5 P1 0.45 1.92 4.11 2.78 [2.13-3.44] 2.54 [2.09-3.09] 
 P2 0.00 1.29 3.12 2.14 [1.59-2.70] 2.48 [2.03-3.02] 
EX10 P1 0.00 0.00 2.14 1.54 [1.00-2.07] 2.36 [1.83-3.04] 
 P2 0.00 1.31 2.58 2.14 [1.61-2.66] 2.07 [1.71-2.52] 
EX30 P1 3.66 8.53 13.94 10.66 [8.60-12.72] 7.84 [6.24-9.85] 
 P2 0.12 2.10 4.87 3.37 [2.62-4.11] 3.06 [2.44-3.83] 
 
(NC) normal control; (DC) diabetic control; (EX) experimental; (P1) proximal portion of the pancreas; 
(P2) distal portion of the pancreas. 
6.4.2.5 Somatostatin Staining Intensity 
Somatostatin staining intensity was observed and classified as none, low, moderate or high. 
Figure 6.18 represents somatostatin staining intensity obtained from 100 islets per tissue 
portion (P1 and P2) in each one of the study groups.  
Somatostatin staining intensity in NC group (P1 and P2 portions) was predominantly 
classified as moderate. In the DC and EX groups, somatostatin staining intensity was 
predominantly low, except in the P1 portion of the EX10 group and in the P2 portion of the 
EX3 group, where islets were predominantly negative for somatostatin. Between day 3 and 
day 30, EX pancreata collectively had more islets (n=263) where somatostatin was absent 
from the islet compared to DC pancreata collectively (n=165). 
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Figure 6.18. Chart showing somatostatin staining intensity obtained from 100 islets per tissue portion 
(P1 and P2) in NC, DC and EX groups. (NC) normal control; (DC) diabetic control; (EX) 
experimental; (P1) proximal portion of the pancreas; (P2) distal portion of the pancreas. 
6.4.2.6 Somatostatin Distribution 
Somatostatin positive cells in NC, DC and EX groups were classified according to their 
locations within the islet as core (C-classification), mantle (M-classification) or both (B-
classification). The distribution of somatostatin positive cells in the P1 and P2 portions of the 
pancreas of each study group is represented in Figure 6.19. 
Somatostatin positive cells were predominantly located in the mantle of islets (M-
classification) in the P1 and P2 portions of the NC group; a few somatostatin positive islets, 
however, had C-classification and B-classification. The somatostatin positive cells were 
scattered in the mantle as single cells, pairs of cells or in small groups (3-4 cells). Following 
diabetes induction, somatostatin distribution became disrupted in both the DC and EX groups. 
In all of these groups somatostatin positive cells were predominantly observed in both the 
core and mantle of islets (B-classification).  Compared to the NC group, the treated groups 
also show an increased number of islets with C-classification. Similar to the NC islets, 
somatostatin positive cells were observed as single cells, pairs of cells or small groups of cells 
(3-4 cells) in the DC and EX islets. 
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Figure 6.19. Chart showing distribution of somatostatin positive cells within the islets of NC, DC and 
EX groups. (C-classification) core; (M-classification) mantle; (B-classification) both; (NC) normal 
control; (DC) diabetic control; (EX) experimental; (P1) proximal portion of the pancreas; (P2) distal 
portion of the pancreas. 
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6.4.3 Islet composition in the pancreas 
Hormone fractions for insulin, pancreatic polypeptide, glucagon and somatostatin were used 
to summarise the comparative islet composition of P1 and P2 portions of the pancreas in NC 
and DC0 groups (Figure 6.20), in DC3 and EX3 group (Figure 6.21), in DC5 and EX5 groups 
(Figure 6.22), in DC10 and EX10 groups (Figure 6.23) and in DC30 and EX30 groups (Figure 
6.24).  
 
 
 
Figure 6.20. Pie charts showing islet composition in the P1 and P2 portions of the pancreas of the NC 
group and the DC0 group. (NC) normal control; (DC0) diabetic control baseline; (P1) proximal 
portion of the pancreas;  (P2) distal portion of the pancreas. 
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Figure 6.21. Pie charts showing islet composition in the P1 and P2 portions of the pancreas of the 
DC3 group and the EX3 group. (DC3) diabetic control day 3; (EX3) experimental day 3; (P1) 
proximal portion of the pancreas; (P2) distal portion of the pancreas. 
 
 
 
Figure 6.22. Pie charts showing islet composition in the P1 and P2 portions of the pancreas of the 
DC5 group and the EX5 group. (DC5) diabetic control day 5; (EX5) experimental day 5; (P1) 
proximal portion of the pancreas; (P2) distal portion of the pancreas. 
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Figure 6.23. Pie charts showing islet composition in the P1 and P2 portions of the pancreas of the 
DC10 group and the EX10 group. (DC10) diabetic control day 10; (EX10) experimental day 10; (P1) 
proximal portion of the pancreas; (P2) distal portion of the pancreas. 
 
 
 
Figure 6.24. Pie chart showing islet composition in the P1 and P2 portions of the pancreas of the 
DC30 group and the EX30 group. (DC30) diabetic control day 30; (EX30) experimental day 30; (P1) 
proximal portion of the pancreas; (P2) distal portion of the pancreas. 
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7. DISCUSSION 
7.1 BLOOD GLUCOSE, BODY WEIGHT AND SERUM INSULIN 
Diabetes was successfully induced over a period of 10 days by a single intraperitoneal 
injection of STZ at a dose of 45 mg/kg. The average BGL was above 23 mmol/L throughout 
the diabetes induction period and peaked on day 10 post-STZ injection (29.39 mmol/L). 
During the experimental period hyperglycaemia remained stable, with body weight decreasing 
over time. Other studies have successfully used STZ at similar and higher doses (40-70 
mg/kg) to produce diabetic rats within as little as two days (Coskun, Ocakci et al. 2004, 
Coskun, Kanter et al. 2005, Adewole, Caxton-Martins et al. 2006,Akinola, Caxton-Martins et 
al. 2010, Toma, Makonnen et al. 2015). However, there is a risk of acute STZ toxicity and 
mortality between day 6 and 10 post-administration (Deeds, Anderson et al. 2011). Our study 
subjected animals that survived 10 days diabetes induction with stable hyperglycaemia to 
PDL treatment. Additionally, to ensure effectiveness of this relatively low dose of STZ, 
animals were fasted prior to STZ injection. Lowering blood glucose prior to STZ injection 
results in more severe beta cell destruction compared to the same dose of STZ administered to 
animals in a fed state (Cavelti-Weder, Shtessel et al. 2013). This is due to the fact that less 
glucose is occupying beta cell GLUT2 receptors, allowing STZ to readily enter the beta cell 
(Cavelti-Weder, Shtessel et al. 2013). 
No spontaneous recovery from STZ-induced diabetes was observed in control groups over the 
total of 40 days (diabetes induction period and experimental period). This is in agreement 
with the findings of previous studies, specifically in models or groups where no intervention 
was done to aid glycaemic control (Coskun, Kanter et al. 2005, Adewole, Caxton-Martins et 
al. 2006, Yin, Tao et al. 2006, Akinola, Caxton-Martins et al. 2010). Endogenous beta-cell 
recovery in STZ-diabetic mice is, however, reported to occur following 120 days of islet 
transplantation or insulin implant (Grossman, Lee et al. 2010, Yin, Tao et al. 2006).  Since the 
current study aimed to induce endogenous beta-cell recovery by PDL alone, no insulin was 
administered to diabetic animals as this could interfere with the results.  
The animals’ body weights during the diabetes induction period decreased following the 
overnight fast. Following STZ injection the weights remained decreased and did not return to 
baseline values even 10 days post-STZ injection. During the subsequent experimental period 
body weight fluctuated, with no tendency to increase in the DC animals as would be expected 
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in non-diabetic animals. Body weight of the DC animals also did not show a tendency to 
decrease over time during the experimental period; these findings are concomitant with the 
repot of Toma et al. (2015). Other researchers, however,  reported decreasing body weight in 
STZ-induced diabetic rats over extended periods of time (28-30 days) ( Coskun, Kanter et al. 
2005, Adewole, Caxton-Martins et al. 2006). In the EX groups, body weight decreased with 
time (EX30) compared to DC groups where body weight remained relatively constant. This 
observation was not in line with the literature that reports that PDL does not affect body 
weight of non-diabetic animals (Xu, D'Hoker et al. 2008, Rankin, Wilbur et al. 2013). 
Serum insulin levels were variable, with most of the measurements falling outside the range 
of the standard curve. It is interesting to note that one animal in the NC group (that was within 
the range of the standard curve) had similar values to one animal in the EX30 group, although 
this result cannot be conclusive. Based on this observation, it may be worth further 
investigating serum insulin levels in our model. It is expected that using fasting serum 
samples with an ELISA kit with higher specificity for rat samples may yield better results.  
7.2 HISTOMORPHOLOGY OF THE PANCREAS 
The portions of the pancreata were morphologically assessed in NC, DC and EX groups. In 
the DC groups, the exocrine compartment of the pancreas was healthy, with similar 
histomorphology as observed in the NC group. The histomorphology of the exocrine 
compartment in the P1 portions of the pancreas in the EX groups was similar to normal, while 
P2 portions presented with deleterious changes in the exocrine compartment, characterised by 
the initial apoptosis of acinar cells with concomitant proliferation of the duct cells. This 
phenomenon is consistently reported in the literature for rodent models of PDL (Tchokonte-
Nana 2011, Cavelti-Weder, Shtessel et al. 2013, Hakonen, Ustinov et al. 2011, Chintinne, 
Stange et al. 2012, Rankin, Wilbur et al. 2013). Acinar damage is said to be induced by the 
premature activation of the pancreatic digestive enzymes within the acinar cells due to 
disruption of calcium-signalling following PDL (Mooren, Hlouschek et al. 2003). An early 
study provided evidence that some acinar cells may also convert to duct cells following PDL 
(Churg, Richter 1972). 
In our diabetic model, the morphological changes observed in the P2 portions on day three 
and day five post-PDL are comparable to the third and fourth landmarks described by 
Tchokonte-Nana (2011) in a non-diabetic rat model (Tchokonte-Nana 2011). These changes 
were widespread acinar deletion, oedema and ductal proliferation on day three and 
Stellenbosch University  https://scholar.sun.ac.za
72 
  
remodelling of the exocrine pancreas became evident by day five post-PDL, where lobes with 
intact exocrine morphology were observed. This remodelling persisted on day 10 and 30 post-
PDL in all animals in our study.  
The assessment of the endocrine compartment in the DC groups revealed progressive necrotic 
changes, including degranulation, hydropic changes and pyknotic nuclei. These changes 
correlate with the histopathology previously reported in STZ-induced diabetic rats (Coskun, 
Ocakci et al. 2004, Coskun, Kanter et al. 2005, Adewole, Caxton-Martins et al. 2006, 
Akinola, Caxton-Martins et al. 2010). Similarly, necrotic changes were found in the islets of 
the EX groups, except in the P1 and P2 portions of the pancreas in the EX30 group, where 
recovery in islet cell morphology was noted. This recovery could possibly be attributed to the 
remodelling effect of PDL. Moreover, previous studies using PDL alone or in combination 
with STZ reported that the islets are not damaged by PDL (Tchokonte-Nana 2011, Cavelti-
Weder, Shtessel et al. 2013), this could substantiate the effects of PDL remodelling in our 
study.  
7.3 ISLET COMPOSITION AND ARCHITECTURE IN THE PANCREAS 
7.3.1 Islet composition and architecture in the NC group 
In the present study normal islet (NC group) composition varied between the P1 (proximal) 
and P2 (distal) portions of the pancreas. Normal islets in the P1 portion consisted of 58.72% 
beta cells, 4.93% PP cells, 25.26% alpha cells and 2.15% delta cells, while normal islets in the 
P2 portion had 68.72% beta-cells, 5.30% PP cells, 21.05% alpha cells and 3.93% delta cells. 
Beta and delta cell fractions were higher in the normal P2 portion compared to the P1 portion. 
These results are in line with normal rodent islet composition reported in the literature 
(Erlandsen, Hegre et al. 1976, Weiczoreck, Pospischil et al. 1998, Zafar, Mughal 2002, 
Brissova, Fowler et al. 2005, Steiner, Kim et al. 2010, Ruipan, Xiangzhi et al. 2014). 
However, PP cell fraction did not differ between the two portions in the normal pancreas, 
contradicting a previous report that PP cells may be more numerous in the head region of the 
pancreas (Elayat, El-Naggar et al. 1995). Alpha cell fraction is reported to be higher in the P1 
portion (Zafar, Mughal 2002) and this tendency was observed in the present study Previous 
studies have included classifying hormone staining intensity in their evaluation of the diabetic 
pancreas (Coskun, Ocakci et al. 2004, Coskun, Kanter et al. 2005). In the present study, the 
hormone staining intensity in the P1 and P2 portions of the pancreas in the NC group was 
strong in beta, alpha and PP cells, while delta cells had medium hormone staining intensity.  
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Rodent islet architecture, where beta cells occupy the central part of the islet while non-beta 
cells are located at the islet’s periphery, is consistently described in the literature (Erlandsen, 
Hegre et al. 1976, Elayat, El-Naggar et al. 1995, Weiczoreck, Pospischil et al. 1998, Zafar, 
Mughal 2002, Brissova, Fowler et al. 2005, Steiner, Kim et al. 2010). This same general 
architecture was observed in the present study. While most studies using 2D methods to 
visualise rodent islet architecture report that the non-beta cells form a relatively continuous 
mantle layer surrounding the beta-cell core (Erlandsen, Hegre et al. 1976, Weiczoreck, 
Pospischil et al. 1998, Brissova, Fowler et al. 2005), our study reports that non-beta cells 
form a discontinuous mantle layer and that the central beta cell mass extends from the core to 
the mantle area of the islet. Our observations are similar to a report using 3D imaging 
techniques to visualize islet architecture (Kharouta, Miller et al. 2009). 
7.3.2 Islet composition and architecture in DC and EX groups 
7.3.2.1 Beta cells 
Islet beta cell fraction was severely decreased in the DC0 group, compared to the NC group, 
to only 13.58% in the P1 and 22.68% in the P2 portion of the pancreas and remained low or 
further decreased over time in DC and EX groups. This observation is consistent with the 
work of Orci et al. (1976), reporting that even 16 months following STZ injection at a dose of 
45mg/kg beta cells remain decreased. Additionally, the beta cell fraction differences between 
islets in the P1 and P2 portions were distorted in the DC and EX groups, indicating 
disproportionate beta cell loss throughout the pancreas. The observed reduction in beta cell 
fraction is as a result of STZ-induced beta-cell necrosis observed in the DC and EX groups 
and is in line with the literature (Li, Karlsson et al. 2000, Coskun, Ocakci et al. 2004, Coskun, 
Kanter et al. 2005, Adewole, Caxton-Martins et al. 2006, Akinola, Caxton-Martins et al. 
2010, Zhang, Zhang et al. 2012).  
In the DC and EX groups, the few surviving beta cells were scattered throughout the diabetic 
islet, unlike in the NC group where they formed a single central mass in the islet. These 
surviving beta cells did not meet physiological insulin demands and the animals remained 
severely hyperglycaemic. It is reported that even with 25% beta cell survival, there is no 
functional insulin response to glucose challenge in STZ-induced diabetic mice (Meier, 
Ueberberg et al. 2011).  It is proposed that islet architecture (i.e. the clustering of beta cells) is 
important for synchronized and sufficient insulin release from the islet (Aspinwall, Lakey et 
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al. 1999); in this regard the observed disruption in islet architecture in both the DC and EX 
groups may explain the impairment of the function of the remaining beta cells.  
There were very few differences in insulin expression between DC and EX groups. However, 
beta cell hormone staining intensity was even more decreased in EX groups compared to DC 
groups, indicating that PDL did not have a positive effect on restoring beta cell function in EX 
groups. Furthermore, the beta cell fraction was significantly decreased in the P1 portion of the 
EX30 group when compared to the P1 portion of the DC30 group. This observation suggests 
that PDL negatively affects beta cell fraction in the P1 portion of the pancreas. This is a novel 
observation, as previous reports indicated no effect of PDL on beta cell fraction in the P1 
portion of the pancreas (Wang, Kloppel et al. 1995, Hakonen, Ustinov et al. 2011, Cavelti-
Weder, Shtessel et al. 2013).  
Many studies report beta cell expansion in the post-ligated portion (P2 portion) of the 
pancreas following PDL in non-diabetic animals (Xu, D'Hoker et al. 2008, Solar, Cardalda et 
al. 2009b, Wang, Zhang et al. 2011, Hakonen, Ustinov et al. 2011, Van de Casteele, Leuckx 
et al. 2013, De Groef, Leuckx et al. 2015). Yet, in the present study the P2 portion of DC and 
EX groups had similar beta cell fractions, indicating that PDL had no effect on beta cell 
fraction in the P2 portion of the pancreas. Previous studies may have overestimated beta cell 
formation as their measurements are normalised to total pancreatic area without taking into 
account the destruction of the exocrine compartment of the pancreas (Cavelti-Weder, Shtessel 
et al. 2013). As demonstrated by Chintinne et al. (2012) beta cell mass (calculated per total 
area of the pancreas) may be seemingly increased without any significant change in beta cell 
number (Chintinne, Stange et al. 2012). Furthermore, a recent study that quantified total beta 
cell mass and pancreatic insulin content found no changes following PDL (Rankin, Wilbur et 
al. 2013). 
Due to the deficiency in methods for beta cell mass measurements in the PDL model, the 
present study used beta cell fraction as an indication of beta cell loss and formation. Beta cell 
fraction is calculated per islet area and is, therefore, not biased by the changes in the exocrine 
compartment of the P2 portion of the pancreas following PDL. Nonetheless, PDL did not 
induce beta cell formation within pre-existing islets when applied 10 days following STZ 
injection. This finding supports previous work of Cavelti-Weder et al. (2013), who applied 
PDL six to seven days post-STZ injection (this was in combination with islet transplants to 
aid glycaemic control). However, beta cell neoformation was achieved by Chung et al. (2010) 
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when applying PDL only 30 minutes following alloxan injection to destroy beta cells (Chung, 
Hao et al. 2010). This difference in results could be explained by the difference in the time 
allowed between beta cell ablation and PDL treatment, or by the respective use of STZ and 
alloxan. 
7.3.2.2 PP cells 
In the DC and EX groups PP cell fractions were increased compared to the NC group and PP 
cells were displaced (now found in both the islet core and mantle) by the expanded alpha cell 
layer of DC and EX islets. This increase in PP cell fraction in the diabetic pancreas is 
consistent with the findings of Zang et al. (2012) and Ruipan et al. (2014), while Li et al. 
(2000) in contrast reports no change in PP cell numbers in the STZ-induced diabetic pancreas. 
The results of these authors may look contradictory due to the fact that Li et al. (2000) 
calculated the mean number of PP cells per islet and did not investigate PP cell fraction. 
Changes in the PP cell fraction observed in the DC and EX groups of the present study could 
be the result of disproportionate changes in the other islet cell type fractions. However, the 
fact that larger groups of PP cells were observed within the diabetic islets may indicate the 
possibility of an increase in PP cell number. PP cell fraction was significantly higher in the P1 
portion of the EX3 group and in the P2 portion of the EX10 group when respectively 
compared to their DC groups. In the non-diabetic pancreas, PP cells are reportedly deleted 
from the islet mantle following PDL (Page, du Toit et al. 2000). To our knowledge this is the 
first study investigating changes in PP cell fraction in a model combining STZ and PDL. 
7.3.2.3 Alpha cells 
Changes in alpha cell composition and distribution were similar in the DC and EX groups. 
The alpha cell fraction increased to 59.23% in the P1 portion and 60.54% in the P2 portion of 
the DC0 group. The discontinuous alpha cell layer observed in the NC group appeared 
expanded and stretched from the mantle to the core of the islet in the DC and EX groups. In 
DC and EX groups there was no change in hormone staining intensity compared to the NC 
group, but fewer islets devoid of alpha cells were seen in DC and EX groups. Alpha cell 
fractions in the DC and EX groups were significantly increased compared to normal for the 
duration of the 30 day experimental period. Previous studies also reported that STZ-induced 
diabetic islets have increased alpha cell fractions (Orci, Baetens et al. 1976, Zhang, Zhang et 
al. 2012, Ruipan, Xiangzhi et al. 2014, Plesner, Ten Holder et al. 2014), but authors do not 
agree on whether total alpha cell area or mass is increased in the diabetic pancreas. The report 
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from Meier et al. (2006 & 2011) indicated no change in alpha cell mass in the diabetic 
pancreas and is supported by recent findings from Haung et al. (2013). In the latter study it is 
reported that pancreatic glucagon content is increased, without alpha cell number being 
increased; these alpha cells did, however, have larger glucagon granules and increased 
glucagon exocytosis (Huang, Rupnik et al. 2013). In contrast, alpha cell number is reported to 
be increased in multiple mouse models of STZ-induced diabetes (Li, Karlsson et al. 2000, 
Lee, Wang et al. 2011a, Zhang, Zhang et al. 2012, Takeda, Fujita et al. 2012, Plesner, Ten 
Holder et al. 2014).  
Although total pancreatic alpha cell area was not investigated in the current study, the alpha 
cell fraction within each islet appeared to be increased following STZ injection. It should be 
considered that alpha cell fraction will naturally increase due to the loss of beta cells from the 
islet (Li, Karlsson et al. 2000), however, this does not explain the increased thickness of the 
alpha cell layer that was observed in the present study. This expansion of the alpha cell layer 
from the periphery into the core of the islet may indicate increased alpha cell numbers. Alpha 
cell expansion may have occurred via cell proliferation (involved in self-duplication and 
regeneration) and/or via neogenesis from multipotent progenitors, as was previously reported 
in a mouse model of STZ-induced diabetes (Zhang, Zhang et al. 2012). Interestingly, 
statistical analyses in the current study indicate that alpha cell fraction did not continue to 
increase in DC and EX groups over time, but remained at the increased level observed on day 
10 post-STZ injection.  
In the non-diabetic pancreas, alpha cell volume has been reported to increase following PDL 
(Wang, Zhang et al. 2011, Cai, Yuchi et al. 2014).Authors did not take into account the 
decreased total pancreatic area of the PDL pancreas when calculating alpha cell volume 
(similar to reported beta cell mass calculations). Nevertheless, an increase in absolute alpha 
cell number following PDL in the non-diabetic pancreas has also been observed (Chintinne, 
Stange et al. 2012). In contrast, Page et al. (2000) reported that alpha cells are deleted from 
the islet mantle, subsequently forming a very thin discontinuous layer at the islet periphery 
following PDL. In the present study, alpha cells formed a relatively thick layer following PDL 
with alpha cell fraction significantly lower in the P2 portion of the EX10 group compared to 
the P2 portion of the DC10 group; this may indicate deleterious effects of PDL on alpha cells 
in the diabetic pancreas. However, alpha cell fraction in the P2 portion of the EX10 group did 
not significantly differ from the alpha cell fraction in the P2 portion of the DC0 group. 
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7.3.2.4 Delta cells 
Delta cell fractions varied in the DC and EX groups, fluctuating between higher and lower 
fractions compared to the NC group. Increased delta cell fraction in the diabetic pancreas is 
reported in the literature ( Orci, Baetens et al. 1976, Ruipan, Xiangzhi et al. 2014, Plesner, 
Ten Holder et al. 2014, Alan, Olejar et al. 2015), but this finding was not consistent in the 
present study. Orci et al. (1976) suggested that increased delta cell numbers may indicate an 
adaptive, although unsuccessful, effort by the islets to decrease hyperglucagonemia associated 
with diabetes, with increased local somatostatin release. Although serum glucagon levels were 
not evaluated in the present study, it stands to reason that hyperglucagonemia may very well 
have accompanied the increase in alpha cell fractions observed in the present study.  The 
distribution of delta cells within the islet shifted from the mantle to being observed in both the 
core and mantle of the islet in both the DC and EX groups. The disruption of delta cell 
distribution was similar in these groups, although the EX groups presented more frequently 
with islets devoid of delta cells. 
In the non-diabetic pancreas, delta cells are deleted from the islet mantle following PDL 
(Page, du Toit et al. 2000). In line with this observation, delta cell fraction was significantly 
lower in the P1 portion of the EX3 group and in the P2 portion of the EX10 group compared 
to their respective control groups. However, on day 30 the delta-cell fraction was increased in 
the P1 portions of both the DC30 and EX30 groups; moreover, delta cell fraction was 
significantly higher in the P1 portion of the EX30 group compared to the P1 portion of the 
DC30 group.  
It is interesting to note that, while the literature discussed reported changes only in the P2 
(post-ligature) portions of the pancreas, the present study shows that hormone fractions in the 
P1 portions of the pancreas were also affected following PDL. Furthermore, the only time at 
which PDL altered the diabetic islet composition in the P2 portions was on day 10. In this 
portion, the PP cell fraction was increased, while alpha and delta cell fractions were decreased 
in the EX10 group compared to the DC10 group. At all other days, no differences were found 
between islet composition in the P2 portions of DC and EX groups. It could be speculated that 
the observed recovery in the exocrine compartment from day 5 is followed by transient 
remodelling of islet composition on day 10. 
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8. CONCLUSION 
The project set out to establish islet composition and architecture in diabetic rats following 
pancreatic duct ligation, and to compare the portions of the pancreas proximal and distal to 
the ligature. This study demonstrated that the effect of pancreatic duct ligation on the 
morphology of the diabetic pancreas was similar to that reported in the non-diabetic pancreas. 
Interestingly, the islets in the experimental 30 day group presented with some apparent 
morphological recovery. Despite this morphological recovery, islet composition and 
architecture remained disrupted in the present model combining beta cell ablation and 
pancreatic duct ligation. Furthermore, pancreatic duct ligation did not restore body weight or 
normoglycemia. 
The portion of the pancreas proximal to the ligation had a decreased beta cell fraction and 
increased delta cell fraction 30 days following pancreatic duct ligation. These observed 
changes in diabetic islet composition in the part of the pancreas proximal to the ligature are 
novel findings. There was no change in the diabetic islet composition in the portion of the 
pancreas distal to the ligature thirty days following pancreatic duct ligation.  
Finally, pancreatic duct ligation did not restore normal islet composition, architecture and 
physiological glucose homeostasis in STZ-induced diabetic rats in this study. It is possible 
that the effects of pancreatic duct ligation are limited in an STZ model due to severe damage 
to pre-existing beta cells and expansion of the alpha cell fraction. Further investigation is 
warranted to explain the morphological remodelling observed thirty days following pancreatic 
duct ligation with no improvement in beta cell fraction and function.  
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9. STRENGTHS, LIMITATIONS AND PERSPECTIVES 
The strength of this study lies in the fact that the islet composition and architecture of the four 
main islet cell types have been established in both portions of the pancreas (proximal and 
distal to the ligature) in a diabetic PDL model. Hormone fractions were evaluated as part of 
islet composition. These fractions were also used to indicate the destruction or formation of 
the various cell types analysed. Since the hormone fractions were determined per islet area, it 
was not affected by the changes in exocrine pancreas observed in the P2 portion of the 
pancreas following ligation. Therefore, hormone fractions in the P2 portion of the PDL 
pancreas could be compared to all other control P1 and P2 portions without being influenced 
by changes in the exocrine compartment.  
However, one of the limitations of the study is that other parameters (apart from hormone 
fractions) to assess the effects of PDL were not included. For example, changes in islet size 
and compositional differences between small and large islets, induction of endocrine 
progenitor activity and replication rate of the islet cell types were not investigated.  
The inconclusive serum insulin assessment was also a limitation. Future studies combining 
STZ and PDL should further investigate serum insulin levels from fasted blood samples and 
with an ELISA kit with higher specificity for rodent samples. Serum glucagon levels can also 
be included to assess possible hyperglucagonemia, and this could be correlated with the 
hormone fractions and staining intensity observed in the pancreas to highlight the 
physiological significance of the micro-anatomical changes observed. 
In perspective, we suggest that the effects of PDL should be investigated in a type 2 diabetic 
model, where there is limited damage to pre-existing beta cells, for comparison with the 
present study. 
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APPENDICES  
APPENDIX A: Standard rat pellets 
 Aquanutro Laboratory Animal Food, Rodent Breeder (Nutrocience (Pty) Ltd, 
Malmesbury, South Africa) 
 
APPENDIX B: Materials and methods - Blood glucose and body weight measurments 
Materials: 
 GlucoPlus Meter (GlucoPlus, Montreal, Canada) 
 GlucoPlus Blood Glucose Test Strip (GlucoPlus, Montreal, Canada) 
 Electronic scale (TE1502S, Sartorius, Germany) 
Methods: Blood glucose measurements 
 A small blood sample was collected from the tip of the animal’s tail by gently pricking the 
tail with a sterile lancet 
 The blood drop was collected using a glucose test strip inserted into the  glucometer  
 The reading appeared on the glucometer’s screen 
 
APPENDIX C: Materials - Diabetes induction 
 Streptozocin (Sigma-Aldrich, South Africa) 
 Sodium citrate buffer, pH 4.5, 10mM (Kimix Chemicals, Cape Town, South Africa) 
 Syringes 
 Needles, 27G, BD Microlance 3 (Beckton Dickinson SA, Gauteng, South Africa) 
 
APPENDIX D: Study groups 
Table D: Study groups 
 Study group Sub-group 
Non-diabetic  Normal control (n=6) - 
Diabetic 
Diabetic control (n=27) 
DC day 0 (n=6) 
DC day 3 (n=6) 
DC day 5 (n=5) 
DC day 10 (n=5) 
DC day 30 (n=5) 
Experimental (n=22) 
EX day 3 (n=6) 
EX day 5 (n=6) 
EX day 10 (n=5) 
EX day 30 (n=5) 
 Total: n=55 
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APPENDIX E: Materials - Pancreatic duct ligation 
 Isofor  (Safeline Pharmaceuticals (Pty) Ltd, Roodepoot, South Africa ) 
 Electric shaver  
 Alcohol 70%  
 Surgical instruments: scalpel, clamps, scissors, forceps, cotton buds  
 Zeiss OPMi-1 operating microscope (Carl Zeiss, AG, Oberkochen, Germany) 
 DISMED Povidine Iodine solution (10%) (Dismed Pharma (Pty) Ltd, Randjes Park, South 
Africa) 
 Resorbable suture material: Safil green 3/0 synthetic absorbable surgical suture, 
polyglycolic acid coated braided (Phodiso Home & Hospital Services (Pty) Ltd, 
Newlands, South Africa)  
 Non-resorbable suture material: CliniSilk 5/0 black braided silk suture (CliniSut (Pty) Ltd, 
Port Elizabeth, South Africa) 
 Baytril 5% Injectable Solution (Bayer (Pty) Ltd, Gauteng, South Africa) 
 Temgesic 1ml (Schering-Plough (Pty) Ltd, Woodmead, South Africa)  
 1 mL BD InsulinSyringe with Permanently Attached Needle (Beckton Dickinson SA, 
Gauteng, South Africa) 
 
APPENDIX F: Materials and methods – Blood sample collection and ELISA 
Materials: 
 Syringes (10ml slip tip, Beckton Dickinson SA, Gauteng, South Africa) 
 Needles, 27G, BD Microlance 3 (Beckton Dickinson SA, Gauteng, South Africa) 
 BD Vaccutainer SST II Advance blood collection tubes(Beckton Dickinson SA, Gauteng, 
South Africa) 
 Insulin human ELISA kit (AB100578, Abcam, BIOCOMbiotech, Centurion, South 
Africa) 
 Microplate reader (FLUOstar Omega, BMG Labtech GmbH, Ortenberg, Germany) 
 Precision pipettes (2µl to 1ml)  
 Adjustable 1-12ml pipettes 
 100ml and 1L graduated cylinder 
 Absorbent paper 
 Distilled water 
 Tubes (50ml) 
 Software for ELISA data analysis (MyAssays, BIOCOMbiotech, Centurion, South Africa) 
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Methods 
 Reagents and standards were prepared according to the ab100578 Insulin Human ELISA 
Kit protocol 
 Plasma samples were not diluted for this protocol 
 All standards and samples were run in duplicate, 4 samples from each study group were 
used 
 Standards and samples were loaded into the wells of the microplate as shown in the table 
below: 
Table F: Microplate (96-well) 
 1 2 3 4 5 6 7 8 9 10 11 12 
A Std 1 Std 1 NCA NCA DC3A DC3A DC10A DC10A EX3C EX3C EX10A EX10A 
B Std 2 Std 2 NCB NCB DC3C DC3C DC10B DC10B EX3D EX3D EX10B EX10B 
C Std 3 Std 3 NCC NCC DC3D DC3D DC10C DC10C EX3E EX3E EX10D EX10D 
D Std 4 Std 4 NCD NCD DC3F DC3F DC10D DC10D EX3F EX3F EX10F EX10F 
E Std 5 Std 5 DC0A DC0A DC5A DC5A DC30A DC30A EX5A EX5A EX30C EX30C 
F Std 6 Std 6 DC0D DC0D DC5B DC5B DC30B DC30B EX5B EX5B EX30D EX30D 
G Std 7 Std 7 DC0E DC0E DC5C DC5C DC30C DC30C EX5D EX5D EX30E EX30E 
H Blank Blank DC0F DC0F DC5D DC5D DC30F DC30F EX5F EX5F EX30F EX30F 
 
 The assay procedure was followed according to the ab100578 Insulin Human ELISA Kit 
protocol 
 Immediately after the assay procedure was complete, the microplate was inserted into a 
microplate reader to determine absorbance at 450nm 
 Data was imported into Excel and transferred to the online MyAssays software for 
analysis 
APPENDIX G: Materials and methods - Standard histological processing 
Materials: 
 Tissue processor 
 70%, 80%, 95%, 99% ethanol 
 Parrafin wax (Paraplast; melting point 58ºC) 
 Xylene (Kimix Chemicals, Cape Town, South Africa) 
 Embedding moulds 
Method: 
 Fix tissue in formalin for 48 hours 
 Process tissue using the tissue processor (Table F) 
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 Embed processed tissue in paraffin and block 
Table G: Tissue processing protocol 
Step Solution Time (min) Temperature (ºC) 
1 70% Ethanol 30 40 
2 80% Ethanol 30 40 
3 95% Ethanol 45 40 
4 95% Ethanol 45 40 
5 100% Ethanol 45 40 
6 100% Ethanol 45 40 
7 100% Xylene 45 40 
8 100% Xylene 45 40 
9 Paraffin 30 58 
10 Paraffin 30 58 
11 Paraffin 30 58 
12 Paraffin 30 58 
 
APPENDIX H: Materials – Histology 
 Formalin 10% 
 Surgical blade, forceps 
 50ml sample bottels 
 Embedding Cassette (SPL Life Sciences, Pocheon, Korea) 
 paraffin wax (Paraplast; melting point 58ºC) 
 Leica EG 1160 Embedder 
 Leica Auto Stainer XL (Leica ST5010, Serial number 1732/07.2007) 
 Leica RM 2125 RT microtome 
 Leica Bond Autostainer (SMM Instruments (Pty) Ltd, Midrand, South Africa) 
 Bond Polymer Refine Detection Kit (SMM Instruments (Pty) Ltd, Midrand, South Africa) 
 Bond Polymer Refine Red Detection Kit (SMM Instruments (Pty) Ltd, Midrand, South 
Africa) 
 BondTM Software ©2009, Version 4.0 (Leica Biosystems, Melbourne, Australia) 
 Xylene (Kimix Chemicals, Cape Town, South Africa) 
 Ethanol (99% & 96%) 
 Acid alcohol (1%) 
 Mayer’s Haematoxylin (Kimix Chemicals, Cape Town, South Africa) 
 Eosin Yellowish (Kimix Chemicals, Cape Town, South Africa) 
 Plastic rack 
 Ammonia (0.2%) 
 Bio-Scan Microscope Slides Frosted (Trifal Imaging, Chatsworth, USA) 
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 Bio-Scan Microscope Slides Positive Charge (Trifal Imaging, Chatsworth, USA) 
 Cover slips 
 PDX Mountant (Kimix Chemicals, Cape Town, South Africa) 
 Pariodic acid 
 Distilled water 
 Schiff’s solution 
 Tap water 
 Harris’s Haematoxylin 
 Staining rack 
 Glass container 
 Coplin staining jar 
 
APPENDIX I: H&E staining protocol 
 Place slides into the plastic rack and into the autostainer, then following the pre-
programmed procedure as tabulated below 
Table E: H&E staining protocol 
Step Solution Time  Repetitions 
1 Xylene 10 min 2 
2 Ethanol (99%) 5 min 2 
3 Ethanol (96%) 2 min 1 
4 Ethanol (70%) 2 min 1 
5 Distilled water 5 sec 1 
6 Haematoxylin 8 min 1 
7 Running water 5 min 1 
8 
Ethanol (1% acid 
alcohol) 
30 sec 1 
9 Running water 1 min 1 
10 Ammonia (0.2%) 45 sec 1 
11 Running water 5 min 2 
12 Ethanol (96%) 10 dips 1 
13 Eosin 45 sec 1 
14 Ethanol (96%) 5 min 2 
15 Xylene 5 min 2 
 
 When staining procedures are complete, mount a cover slip on the glass slides with PDX 
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APPENDIX J: IHC staining protocol and manual rehydration 
Table J1: Automated IHC double staining protocol 
Step Solution Incubation Time Temperature 
1 Bond Wash Solution 0 min 72˚C 
2 Bond Wash Solution 0 min 72˚C 
3 Bond Wash Solution 0 min Ambient 
4 Alcohol 0 min Ambient 
5 Alcohol 0 min Ambient 
6 Alcohol 0 min Ambient 
7 Bond Wash Solution 0 min Ambient 
8 Bond Wash Solution 0 min Ambient 
9 Bond Wash Solution 0 min Ambient 
10 Bond ER Solution 1 0 min Ambient 
11 Bond ER Solution 1 0 min Ambient 
12 Bond ER Solution 1 20 min 100˚C 
13 Bond ER Solution 1 12 min Ambient 
14 Bond Wash Solution 0 min 35˚C 
15 Bond Wash Solution 0 min 35˚C 
16 Bond Wash Solution 0 min 35˚C 
17 Bond Wash Solution 3 min Ambient 
18 Peroxide Block 5 min Ambient 
19 Bond Wash Solution 0 min Ambient 
20 Bond Wash Solution 0 min Ambient 
21 Bond Wash Solution 0 min Ambient 
22 Primary Antibody 1 30 min Ambient 
23 Bond Wash Solution 0 min Ambient 
24 Bond Wash Solution 0 min Ambient 
25 Bond Wash Solution 0 min Ambient 
26 Post Primary 8 min Ambient 
27 Bond Wash Solution 2 min Ambient 
28 Bond Wash Solution 2 min Ambient 
29 Bond Wash Solution 2 min Ambient 
30 Polymer 8 min Ambient 
31 Bond Wash Solution 2 min Ambient 
32 Bond Wash Solution 2 min Ambient 
33 Deionized Water 0 min Ambient 
34 Mixed DAB Refine 0 min Ambient 
35 Mixed DAB Refine 10 min Ambient 
36 Deionized Water 0 min Ambient 
37 Deionized Water 0 min Ambient 
38 Deionized Water 0 min Ambient 
39 Haematoxylin 5 min Ambient 
40 Deionized Water 0 min Ambient 
41 Bond Wash Solution 0 min Ambient 
42 Deionized Water 0 min Ambient 
43 Primary Antibody 2 15 min Ambient 
44 Bond Wash Solution 0 min Ambient 
45 Bond Wash Solution 0 min Ambient 
46 Bond Wash Solution 0 min Ambient 
47 Post Primary AP 20 min Ambient 
48 Bond Wash Solution 2 min Ambient 
49 Bond Wash Solution 2 min Ambient 
50 Bond Wash Solution 2 min Ambient 
Stellenbosch University  https://scholar.sun.ac.za
101 
  
51 Polymer AP 30 min Ambient 
52 Bond Wash Solution 2 min Ambient 
53 Bond Wash Solution 2 min Ambient 
54 Bond Wash Solution 5 min Ambient 
55 Bond Wash Solution 2 min Ambient 
56 Bond Wash Solution 0 min Ambient 
57 Deionized Water 0 min Ambient 
58 Mixed Red Refine 10 min Ambient 
59 Mixed Red Refine 5 min Ambient 
60 Deionized Water 0 min Ambient 
61 Deionized Water 0 min Ambient 
62 Deionized Water 0 min Ambient 
63 Haematoxylin 5 min Ambient 
64 Deionized Water 0 min Ambient 
65 Bond Wash Solution 0 min Ambient 
66 Deionized Water 0 min Ambient 
Table J2: Manual rehydration protocol 
Step Solution Time  Repetitions 
1 Ethanol (70%) 5 dips 1 
2 Ethanol (96%) 5 dips 1 
3 Ethanol (99%) 5 dips 1 
4 Xylene 1 min 2 
 
APPENDIX K: IHC – Antibodies 
Table K: Summary of antibodies 
Antibody Source Antibody ID Clonality Raised in Dilution 
Anti-insulin BioGenex MU029-UC Monoclonal Mouse 1:1000 
Anti-pancreatic 
polypeptide 
Abcam Ab113694 Polyclonal Rabbit 1:1500 
Anti-glucagon Abcam Ab10988 Monoclonal Mouse 1:5000 
Anti-somatostatin Abcam Ab22682 Polyclonal Rabbit 1:2000 
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APPENDIX L: Raw data – Blood glucose measurements 
Grp ID BL F STZ1 STZ3 STZ5 STZ7 STZ9 d0 d1 d3 d5 d7 d9 d10 d12 d14 d16 d18 d20 d22 d24 d26 d28 d30 
NC A 3.4 
                       
 
B 7.7 
                       
 
C 6.7 
                       
 
D 3.3 
                       
 
E 6.9 
                       
 
F 7.1 
                       DC0 A 6.8 4.7 33.3 27.6 15.1 22.4 20.1 25.2 
                
 
B 6.4 3.7 27.7 20.2 10.7 20.2 20.2 32.1 
                
 
C 6.1 3.7 33.3 23.9 20.7 22.2 33.3 31.6 
                
 
D 6.6 3.9 33.3 23.7 20.8 26.1 26.6 26.7 
                
 
E 6.6 3.6 22.9 23.6 15.6 19.6 28.3 33.3 
                
 
F 6.8 3.6 27.6 20.1 11.2 19.2 19.8 19.8 
                DC3 A 3.9 2.7 16.9 26.7 21.1 13.7 33.3 33.3 29.9 29.1 
              
 
B 6 5.4 33.3 22.9 16.8 33.3 33.3 26.7 33.3 33.3 
              
 
C 4.9 4.7 16.9 22.2 12.1 22.9 26.4 17 26.4 25.7 
              
 
D 7.7 5.1 20.8 24.7 13.6 16.4 33.3 23.4 33.3 33.3 
              
 
E 6.3 4.8 23.3 24.8 17.2 33.3 28.1 33.3 33.3 30.3 
              
 
F 5.7 4.1 19.9 26.9 14.7 22.9 23.5 33.3 15.1 33.3 
              EX3 A 7.4 4.2 23 23.2 33.3 26.7 31.4 33.3 33.3 27.1 
              
 
B 7.1 4.2 33.3 26 33.3 26.8 30.4 33.3 23.1 31.1 
              
 
C 6.7 4.5 19.3 25.9 33.3 17.6 33.3 27.6 16.3 25.6 
              
 
D 7.3 3.7 27.9 25.7 33.3 24 31.1 33.3 33 33.3 
              
 
E 5.9 3.2 33.3 26 30 27.1 24.3 28.1 13.1 20.7 
              
 
F 6.8 3.9 20.7 29.2 30.3 26.4 31.3 31.3 19.4 33.3 
              DC5 A 7.8 4.9 26.1 33.3 33.3 23.8 26.3 27.3 18.8 29.5 25.7 
             
 
B 7.9 4.9 33.3 29.6 33.3 32.9 33.3 33.3 33.3 33.3 33.3 
             
 
C 8 4.9 25.9 24.3 25.4 31 18.4 25.3 26.4 33.3 30.4 
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Grp ID BL F STZ1 STZ3 STZ5 STZ7 STZ9 d0 d1 d3 d5 d7 d9 d10 d12 d14 d16 d18 d20 d22 d24 d26 d28 d30 
 
D 8.1 4.8 17.6 9.2 8.3 5.2 9.2 14.4 11.8 9.1 16 
             
 
F 7.9 5.3 22.7 22.4 31.9 15.7 21.2 21.6 31.1 33.3 27.6 
             EX5 A 8 3.6 28.1 27.8 17.8 24.8 18.4 29.1 27.8 33.3 25.2 
             
 
B 6.9 4.6 24.9 33.3 18.8 19.7 16.9 30.4 27.1 15.4 29.7 
             
 
C 7.3 4.3 32.7 29.7 24.6 27.7 33.3 33.3 33.3 31.6 33.3 
             
 
D 7.3 3.9 31.1 31.1 12.4 18.3 33.3 22.1 9 12.4 8.2 
             
 
E 5.9 3.7 20.1 32.6 23.3 25.7 19.3 33.3 33.3 21.3 30.9 
             
 
F 6.8 3.9 28.6 28.7 18.7 20.1 23.1 33.3 22.4 33.3 12.9 
             DC10 A 7.5 4.6 32.1 33.3 20.6 33.3 33.3 33.3 25 33.3 33.3 30.1 25.6 33.3 
          
 
B 7.1 4.3 23.9 28.7 18.8 26.3 33.3 28.6 33.3 33.3 16.7 30.5 28.6 33.3 
          
 
C 6.6 3.7 12.4 25.7 22 25.3 19 24.4 33.3 33.3 33.3 33.3 21.9 33.3 
          
 
D 6.7 4.2 18.3 28.6 16.7 24.3 22.9 33.1 33.3 33.3 20.4 29.8 22.6 33.3 
          
 
E 6.5 3.9 33.3 28.7 28.7 24.6 33.3 28.9 33.3 33.3 33.3 30.3 33.3 33.3 
          EX10 A 7.7 3.1 24.7 27.1 33.3 20.1 33.3 32.3 33.3 13.9 27.8 19.7 25.9 19 
          
 
B 6.6 4.6 15.7 26 33.3 19.6 32.3 33.3 31.3 15.7 33.3 16.9 33.3 33.3 
          
 
C 6.7 4.6 32.3 32.1 32.9 23.6 19.6 33.3 19.8 33.3 33.3 33.3 33.3 33.3 
          
 
D 6.5 3.5 19.7 33.3 27.4 21.9 33.3 29.6 13.6 25.7 23.6 31.5 24.6 25 
          
 
F 6.7 3.6 18.9 33.2 27.6 21.8 33.3 32.7 19.4 33.3 23.2 26.7 17.7 28.5 
          DC30 A 5.8 6.7 27.3 22.1 27.6 28.4 23.4 25.1 26.1 16.9 25.4 21.7 19.2 19.7 25.9 22.1 33.3 19.3 23.8 23.2 24.1 17.3 22.7 19.4 
 
B 7.3 8.8 24.4 19.4 19.1 11 14.2 18 11.9 7.7 9.8 11.1 7.4 7.7 10.9 12.4 24.2 9.3 9.3 12.2 7.3 6.8 9.4 8.8 
 
C 7.1 4.3 25.6 21.4 20.1 26.8 31.7 33.3 23.7 25.4 25.9 20.9 21.9 26.1 25.6 25 24.2 28.5 28.6 22.6 24.6 26.1 20.5 28.5 
 
E 3.6 4.1 33.3 28.1 26.8 18.6 28.2 33.3 23.8 17 33.3 30.7 26.1 21.2 20.7 26.1 24.4 33.3 30.3 33.3 33.3 33.3 33.3 33.3 
 
F 8.9 5 31.4 24.8 30.3 31.8 28.1 33.3 25.2 30.3 26.1 30.3 32.3 33.3 33.3 31.1 31.3 33.3 33.3 30.8 26.7 33.3 33.3 33.3 
EX30 A 8 4.8 33.3 19.6 28.6 17.5 33.3 33.3 32.3 25.9 33.3 33.3 32.3 33.3 33.3 29.6 33.3 33.3 33.3 25.7 33.3 33.3 33.3 33.3 
 
C 9.1 4.7 24.7 14.3 26.9 16.3 22.7 28.8 18.8 27.8 33.3 21.7 33.3 32.2 26.6 29.4 33.3 33.3 33.3 25.6 33.3 33.3 33.3 33.3 
 
D 7.3 4.1 33.3 19.4 22.7 30.1 33.3 33.3 21.8 33.3 33.3 28.3 29.1 33.3 33.3 33.3 33.3 33.3 33.3 33.3 33.3 33.3 33.3 33.3 
 
E 8.3 4.1 18.3 16.6 28.2 25.3 24.7 33.3 22.7 18 21.3 17.9 20.8 32.5 27.8 27.9 33.3 33.3 33.3 33.3 33.3 33.3 33.3 33.3 
 
F 8.4 5.1 17.6 28.6 26.4 16.8 33.3 32.9 32.1 26.2 24 28.4 25.4 33.3 33.3 22.5 33.3 33.3 33.3 33.3 33.3 33.3 33.3 32.3 
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APPENDIX M: Raw data – Body weight measurements 
Grp ID BL F STZ1 STZ3 STZ5 STZ7 STZ9 d0 d1 d3 d5 d7 d9 d10 d12 d14 d16 d18 d20 d22 d24 d26 d28 d30 
NC A 223 
                       
 
B 226 
                       
 
C 226 
                       
 
D 222 
                       
 
E 219 
                       
 
F 233 
                       DC0 A 215 201 202 200 197 187 184 204 
                
 
B 235 221 220 220 213 203 191 217 
                
 
C 263 250 250 238 230 211 199 222 
                
 
D 233 222 211 215 226 206 197 220 
                
 
E 243 228 227 228 226 214 207 229 
                
 
F 247 232 224 229 226 215 215 240 
                DC3 A 217 213 218 218 218 220 227 222 222 224 
              
 
B 216 210 207 199 192 207 206 200 203 213 
              
 
C 208 202 203 206 206 213 215 214 209 222 
              
 
D 234 226 224 219 215 222 218 219 219 221 
              
 
E 294 289 281 275 264 268 266 261 255 258 
              
 
F 207 202 197 201 200 210 220 210 201 216 
              EX3 A 185 173 171 167 173 155 156 169 172 169 
              
 
B 210 195 195 192 203 178 170 197 190 193 
              
 
C 255 244 242 239 246 220 223 240 239 238 
              
 
D 257 246 24 234 250 224 220 246 242 252 
              
 
E 252 235 235 232 238 218 210 232 221 229 
              
 
F 235 226 222 221 224 202 201 223 220 220 
              DC5 A 207 194 195 202 209 213 220 229 225 236 242 
             
 
B 217 202 201 204 210 216 215 221 211 224 219 
             
 
C 217 204 205 200 207 215 217 216 210 222 219 
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Grp ID BL F STZ1 STZ3 STZ5 STZ7 STZ9 d0 d1 d3 d5 d7 d9 d10 d12 d14 d16 d18 d20 d22 d24 d26 d28 d30 
 
D 204 194 206 211 221 228 234 239 204 248 257 
             
 
F 234 225 218 205 200 203 203 207 207 206 205 
             EX5 A 204 192 189 190 200 185 183 202 197 196 204 
             
 
B 228 214 211 218 221 200 190 225 218 215 227 
             
 
C 235 221 216 212 207 188 188 204 204 203 203 
             
 
D 246 236 242 246 251 243 246 272 260 258 266 
             
 
E 239 227 224 228 231 211 207 236 233 242 245 
             
 
F 236 223 219 214 209 200 190 210 203 199 212 
             DC10 A 198 186 183 184 183 185 175 188 186 190 189 192 182 193 
          
 
B 193 181 191 188 194 200 190 209 207 204 212 218 211 217 
          
 
C 258 248 239 234 233 236 225 236 237 236 234 233 227 240 
          
 
D 232 220 219 217 219 255 206 227 223 222 221 221 216 228 
          
 
E 253 227 225 224 222 222 213 228 223 216 218 226 215 216 
          EX10 A 212 195 199 208 213 200 202 226 223 219 231 230 220 235 
          
 
B 226 213 206 208 205 191 190 212 209 207 208 211 214 214 
          
 
C 251 237 231 224 220 199 192 216 207 210 213 207 207 210 
          
 
D 237 226 225 220 217 200 200 219 212 215 210 221 218 230 
          
 
F 230 215 212 216 217 199 200 220 220 219 222 225 225 234 
          DC30 A 216 211 210 209 213 207 212 212 212 214 221 211 222 222 225 222 228 228 226 226 227 228 223 231 
 
B 214 208 216 206 211 211 216 220 225 227 233 235 236 238 239 239 245 242 245 247 250 250 248 253 
 
C 228 221 212 208 194 201 209 208 208 207 211 209 217 210 209 207 217 217 219 213 218 222 218 220 
 
E 224 214 207 199 204 207 203 201 200 202 200 200 195 191 187 187 186 185 185 186 185 189 189 179 
 
F 234 228 218 213 216 218 216 226 216 222 215 219 214 216 211 219 220 213 211 212 218 215 217 204 
EX30 A 211 198 197 196 208 207 212 215 204 207 205 200 206 206 202 180 194 205 196 207 208 211 213 208 
 
C 208 198 210 212 218 204 193 210 196 200 201 202 200 198 192 157 177 183 184 188 195 184 195 183 
 
D 221 214 222 223 230 183 181 190 185 179 191 178 184 176 180 157 165 172 170 174 177 185 177 164 
 
E 211 201 197 183 190 191 185 197 186 283 174 180 184 180 184 169 171 185 174 183 180 184 189 183 
 
F 216 206 201 190 197 200 192 196 201 189 180 190 182 180 177 139 170 172 165 180 181 178 183 175 
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Insulin 1
a -0.1345
b 0.8855
c 70.79
d 2.152
MSE 0.002643
R² 0.9917
SS 0.03701
SYX 0.06083
Calibrator Conc. Wells Raw
(Corrected)
SEM Backfit Recovery
%
A1 1.71 357.9 119.3
A2 1.63 280.3 93.44
B1 1.36 145.1 96.74
B2 1.28 123.1 82.06
C1 1.18 98.61 131.5
C2 1.03 73.88 98.51
D1 0.703 38.07 101.5
D2 0.627 32.27 86.06
E1 0.406 18.8 100.3
E2 0.394 18.19 97.02
F1 0.214 10.18 108.6
F2 0.188 9.184 97.96
G1 0.0515 4.582 97.75
G2 0.0575 4.765 101.6
   Standard1 300 0.041
   Standard2 150 0.0385
   Standard3 75 0.0725
   Standard4 37.5 0.038
   Standard5 18.75 0.006
   Standard6 9.375 0.013
   Standard7 4.688 0.003
0
0.2
0.4
0.6
0.8
1
1.2
1.4
1.6
1.8
4.6875 46.875
M
e
a
s
u
r
e
m
e
n
t
Concentration
4PL Standard
APPENDIX N: Raw data – Insulin ELISA 
Table O1: Absorbance values at 450nm (displayed as optical density) 
 1 2 3 4 5 6 7 8 9 10 11 12 
A 1.78 1.698 0.152 0.184 0.084 0.091 0.081 0.075 0.12 0.138 0.087 0.131 
B 1.428 1.351 0.113 0.078 0.081 0.107 0.08 0.083 0.098 0.149 0.122 0.187 
C 1.243 1.098 0.105 0.08 0.084 0.107 0.107 0.12 0.129 0.095 0.125 0.21 
D 0.77 0.694 0.102 0.092 0.07 0.101 0.115 0.101 0.128 0.181 0.128 0.108 
E 0.473 0.461 0.085 0.079 0.072 0.1 0.082 0.1 0.097 0.126 0.036 0.346 
F 0.281 0.255 0.082 0.084 0.095 0.1 0.092 0.105 0.102 0.11 0.155 0.116 
G 0.119 0.125 0.077 0.087 0.084 0.079 0.086 0.118 0.11 0.11 0.13 0.128 
H 0.068 0.067 0.082 0.077 0.086 0.092 0.09 0.098 0.127 0.128 0.181 0.124 
 
Results obtained from MyAssays online analysis tool: 
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Sample Dilution Wells Raw Background
Corrected
Conc. Conc.
(Average)
%CV SD SEM
A3 0.152 5.61
A4 0.184 6.66
B3 0.113 4.401
B4 0.078 3.385
C3 0.105 4.163
C4 0.08 3.441
D3 0.102 4.075
D4 0.092 3.784
E3 0.085 3.583
E4 0.079 3.413
F3 0.082 3.497
F4 0.084 3.554
G3 0.077 3.356
G4 0.087 3.64
H3 0.082 3.497
H4 0.077 3.356
A5 0.084 3.554
A6 0.091 3.755
B5 0.081 3.469
B6 0.107 4.223
C5 0.084 3.554
C6 0.107 4.223
D5 0.07 3.161
D6 0.101 4.046
E5 0.072 3.217
E6 0.1 4.016
F5 0.095 3.87
F6 0.1 4.016
G5 0.084 3.554
G6 0.079 3.413
H5 0.086 3.611
H6 0.092 3.784
A7 0.081 3.469
A8 0.075 3.3
B7 0.08 3.441
B8 0.083 3.526
C7 0.107 4.223
C8 0.12 4.613
D7 0.115 4.462
D8 0.101 4.046
E7 0.082 3.497
E8 0.1 4.016
F7 0.092 3.784
F8 0.105 4.163
G7 0.086 3.611
G8 0.118 4.552
H7 0.09 3.726
H8 0.098 3.958
   NCA 1 0.1 6.135 12.1 0.743 0.525
   NCB 1 0.028 3.893 18.5 0.719 0.508
   NCC 1 0.025 3.802 13.4 0.511 0.361
   NCD 1 0.0295 3.929 5.24 0.206 0.146
   DC0A 1 0.0145 3.498 3.44 0.12 0.085
   DC0D 1 0.0155 3.526 1.14 0.0402 0.0284
   DC0E 1 0.0145 3.498 5.73 0.2 0.142
   DC0F 1 0.012 3.427 2.91 0.0998 0.0705
   DC3A 1 0.02 3.655 3.88 0.142 0.1
   DC3C 1 0.0265 3.846 13.9 0.533 0.377
   DC3D 1 0.028 3.888 12.2 0.473 0.334
   DC3F 1 0.018 3.603 17.4 0.625 0.442
   DC5A 1 0.0185 3.616 15.6 0.565 0.4
   DC5B 1 0.03 3.943 2.61 0.103 0.0729
   DC5C 1 0.014 3.483 2.87 0.1 0.0708
   DC5D 1 0.0215 3.697 3.3 0.122 0.0862
   DC10A 1 0.0105 3.385 3.53 0.119 0.0844
   DC10B 1 0.014 3.483 1.72 0.0601 0.0425
   DC10C 1 0.046 4.418 6.24 0.276 0.195
   DC10D 1 0.0405 4.254 6.91 0.294 0.208
   DC30A 1 0.0235 3.757 9.76 0.367 0.259
   DC30B 1 0.031 3.974 6.76 0.269 0.19
   DC30C 1 0.0345 4.082 16.3 0.665 0.47
   DC30F 1 0.0265 3.842 4.27 0.164 0.116
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A9 0.12 4.613
A10 0.138 5.167
B9 0.098 3.958
B10 0.149 5.514
C9 0.129 4.888
C10 0.095 3.87
D9 0.128 4.857
D10 0.181 6.559
E9 0.097 3.929
E10 0.126 4.795
F9 0.102 4.075
F10 0.11 4.312
G9 0.11 4.312
G10 0.11 4.312
H9 0.127 4.826
H10 0.128 4.857
A11 0.087 3.64
A12 0.131 4.949
B11 0.122 4.673
B12 0.187 6.761
C11 0.125 4.765
C12 0.21 7.553
D11 0.128 4.857
D12 0.108 4.252
E11 0.036 2.251
E12 0.346 12.83
F11 0.155 5.706
F12 0.116 4.492
G11 0.13 4.918
G12 0.128 4.857
H11 0.181 6.559
H12 0.124 4.734
H1 0.068 3.106
H2 0.067 3.078
The highlighted samples are outside the range of the standard measurements.
   EX3C 1 0.0615 4.89 8.02 0.392 0.277
   EX3D 1 0.056 4.736 23.2 1.1 0.778
   EX3E 1 0.0445 4.379 16.4 0.719 0.509
   EX3F 1 0.087 5.708 21.1 1.2 0.851
   EX5A 1 0.044 4.362 14.1 0.613 0.433
   EX5B 1 0.0385 4.193 3.99 0.167 0.118
   EX5D 1 0.0425 4.312 0 0 0
   EX5F 1 0.06 4.841 0.449 0.0217 0.0154
   EX10A 1 0.0415 4.295 21.6 0.926 0.655
   EX10B 1 0.087 5.717 25.8 1.48 1.04
   EX10D 1 0.1 6.159 32 1.97 1.39
   EX10F 1 0.0505 4.555 9.39 0.427 0.302
   EX30C 1 0.123 7.542 99.2 7.48 5.29
   EX30D 1 0.068 5.099 16.8 0.859 0.607
   Blank 0 3.092 0.631 0.0195 0.0138
   EX30E 1 0.0615 4.888 0.891 0.0436 0.0308
   EX30F 1 0.085 5.647 22.9 1.29 0.912
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